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Abstract
Coenzyme A (CoA) and CoA thioesters are central to numerous metabolic pathways. However, the
inability to synthesize isotopically labeled CoA has limited analytical methods to measure these
compounds. In this thesis, we developed Stable Isotope Labeling with Essential nutrients in Cell culture
(SILEC), a method to generate isotopically labeled CoA derivatives by growing cells in a labeled CoA
precursor, [13C15N]-pantothenate. Labeled CoA derivatives were used as internal standards in a stable
isotope dilution liquid chromatography-mass spectrometry (LC-MS) method to measure changes in short
chain acyl-CoA species. This assay was also adapted to include measurement of glutathione-CoA
(CoASSG), a mixed disulfide increased in mitochondrial oxidative stress. Menadione significantly
increased intracellular levels of CoASSG, and decreased levels of CoASH through the formation of CoAmenadione adduct. In addition, rotenone, an organic pesticide and potent complex I inhibitor, induced a
dose-dependent decrease in succinyl-CoA and increase in beta-hydroxybutyryl-CoA (BHB-CoA) in multiple
human cell lines, as well as inhibited glucose-derived acetyl-CoA and succinyl-CoA biosynthesis. This
SILEC assay was further adapted for use in freshly isolated human platelets to assess metabolic changes
in Friedreich's Ataxia (FA), an inherited mitochondrial disease caused by mutations in the frataxin gene. FA
patients were found to have significantly decreased acetyl-CoA: succinyl-CoA ratio, consistent with an in
vitro siRNA knockdown model of frataxin. Finally, platelets were demonstrated to serve as a powerful ex
vivo metabolic and toxicologic challenge platform evidenced by treatment with propionate, rotenone and
a number of stable isotope metabolic tracers. Together, these methods provide a paradigm for the
discovery of novel biomarkers for metabolic and mitochondrial disease.
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Abstract

SILEC: A NEW TOOL TO STUDY
MITOCHONDRIAL AND METABOLIC DISEASE

Sankha S. Basu
Ian A. Blair, PhD

Coenzyme A (CoA) and CoA thioesters are central to numerous metabolic
pathways. However, the inability to synthesize isotopically labeled CoA has limited
analytical methods to measure these compounds. In this thesis, we developed Stable
Isotope Labeling with Essential nutrients in Cell culture (SILEC), a method to generate
isotopically labeled CoA derivatives by growing cells in a labeled CoA precursor,
[13C315N]-pantothenate. Labeled CoA derivatives were used as internal standards in a
stable isotope dilution liquid chromatography-mass spectrometry (LC-MS) method to
measure changes in short chain acyl-CoA species. This assay was also adapted to include
measurement of glutathione-CoA (CoASSG), a mixed disulfide increased in
mitochondrial oxidative stress. Menadione significantly increased intracellular levels of
CoASSG, and decreased levels of CoASH through the formation of CoA-menadione
adduct. In addition, rotenone, an organic pesticide and potent complex I inhibitor,
induced a dose-dependent decrease in succinyl-CoA and increase in β-hydroxybutyrylCoA (BHB-CoA) in multiple human cell lines, as well as inhibited glucose-derived
acetyl-CoA and succinyl-CoA biosynthesis. This SILEC assay was further adapted for

v

use in freshly isolated human platelets to assess metabolic changes in Friedreich’s Ataxia
(FA), an inherited mitochondrial disease caused by mutations in the frataxin gene. FA
patients were found to have significantly decreased acetyl-CoA: succinyl-CoA ratio,
consistent with in vitro siRNA knockdown model of frataxin. Finally, platelets were
demonstrated to serve as a powerful ex vivo metabolic and toxicologic challenge platform
evidenced by treatment with propionate, rotenone and a number of stable isotope
metabolic tracers. Together, these methods provide a paradigm for the discovery of
novel biomarkers for metabolic and mitochondrial disease.
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Chapter 1: The metabolic role of CoA and developments in the analytical
measurement of CoA derivatives
Despite the discovery of mitochondria more than one hundred years ago,
biological advances over the past half-century have been largely defined by the discovery
of DNA, the foundation of genetic theory, and the elucidation of the human genome. 1, 2
The parallel development of mitochondrial biology has been largely overshadowed until
recently, as both scientists and clinicians have begun to appreciate the wider role
mitochondria play not only in metabolism, but also in the pathogenesis of a wide variety
of human diseases.3-5 The ability to rigorously and quantitatively measure changes in
mitochondrial metabolites is critical in understanding mitochondrial pathology and
finding biomarkers for many of these diseases.6 A brief introduction is provided for the
reader to better appreciate the research presented in this thesis.

1.1 Mitochondria and metabolic disease
Mitochondria are specialized eukaryotic organelles that provide many of the
bioenergetic requirements of the cell.7 Unlike most organelles, mitochondria contain an
inner and outer membrane. Enclosed within the inner membrane is the mitochondrial
matrix, the location of various metabolic processes such as the Krebs cycle, fatty acid
oxidation (FAO), and oxidative phosphorylation (OXPHOS) (Figure 1.1). Eukaryotic
cells contain hundreds to thousands of mitochondria with a wide range of OXPHOS
capacity, depending on the energy requirements of the tissue.8, 9 Also, unlike other
organelles, mitochondria contain their own DNA (mtDNA), which is distinct from
nuclear DNA (nDNA).10 This peculiarity of mitochondria is explained by the generally
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Figure 1.1 Electron transport chain and oxidative phosphorylation. OXPHOS is
accomplished by a set of five enzymatic complexes (I-V). Complex I is normally the
point of entry for the majority of electrons in the respiratory chain that eventually cause
sequential 1-electron reductions of molecular oxygen to water. In addition, complex I
translocates protons generated by the Krebs cycle from the mitochondrial matrix to the
intermembrane space. This establishes the electrochemical gradient required for ATP
biosynthesis. Complex I (NADH dehydrogenase) and complex II (succinate
dehydrogenase) use NADH and FADH2, respectively, to reduce ubiquinone. This
subsequently reduces cytochrome C (complex III) and complex IV, ultimately reducing
molecular oxygen to form water. Cumulatively, complexes I-IV generate a proton
gradient in the mitochondrial intermembrane space, which reenter the matrix through
ATP synthase (Complex V) to form ATP from ADP. In this way, chemical energy from
carbon sources is converted into ATP, the universal energy currency used in the cell.
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accepted endosymbiotic theory of mitochondrial origin, which proposes that
mitochondria were originally OXPHOS-capable eubacteria that formed a symbiotic
relationship with another microorganism providing increased energy efficiency in
exchange for structural and nutritional advantages.7 It is believed that these eubacteria
eventually evolved to become the modern-day eukaryotic mitochondria. Plant
chloroplasts, which also contain their own DNA, are believed to have arisen through a
similar mechanism.11 It has been suggested that this mitochondrial evolutionary origin
itself may be a factor in the pathogenesis of various diseases.12
A number of genetic diseases have been linked to mutations in mtDNA.4
Although mtDNA contains only 13 genes,13 compared to the greater than 30,000 genes in
nDNA, mutations in these genes can lead to debilitating tissue-specific diseases, most
notably several optic neuropathies.14 Curiously, all mitochondria are inherited from the
egg rather than the sperm so mitochondrial diseases have a unique maternal inheritance
pattern.15 Due to the central role of mitochondria in metabolism and bioenergetics, it is
not surprising that mitochondrial dysfunction often leads to pathologic features in tissues
with higher metabolic energy demands.16 In addition to diseases with mitochondrial
inheritance, mitochondrial dysfunction has been implicated in diabetes,17 heart disease,18
cancer,19 Alzheimer’s disease (AD),20 Parkinson’s disease (PD),21 autism,22 and
numerous other neurological and metabolic diseases.23, 24 In addition, many
environmental toxins, pesticides in particular, are thought to exhibit their toxicity through
inhibition of mitochondrial function.25, 26 As a result, environmental insults, particularly
in the context of genetic predispositions may be the etiological factor of many diseases of
idiopathic origin. There is also mounting evidence clinical manifestations such as
3

idiosyncratic adverse drug reactions may also involve metabolic and mitochondrial
toxicity.27 Central to many of these processes is the molecule coenzyme A (CoA).

1.2 Coenzyme A (CoA)
CoA is a ubiquitous intracellular thiol and coenzyme common to all forms of
life,28 serving both metabolic and detoxification functions, ranging from fatty acid
metabolism to xenobiotic acetylation.29 In fact, it is estimated that CoA is used by 4% of
all cellular enzymes.30 CoA is composed of three components: an ATP moiety, a
cysteinyl group, and a pantethine group, which originates from pantothenate (vitamin B5).
In addition to CoA, pantothenate is utilized in the synthesis of the prosthetic group in
acyl-carrier protein (ACP).31 Plants, fungi and many prokaryotes are capable of
synthesizing pantothenate from its constituent amino acids, valine and aspartate (Figure
1.2).32, 33 Animals, however, are not capable of de novo pantothenate synthesis and as a
result, require it in their diet.34 From pantothenate, CoA is synthesized through five
enzymatic steps.35 The first enzyme, pantothenate kinase, which converts pantothenate to
pantethine-phosphate, is the rate-determining step of CoA biosynthesis.36 Pantothenate
deficiency is rare in humans, but can manifest clinically in neurological, gastrointestinal
and metabolic symptoms, all of which can be reversed by pantothenate
supplementation.37
CoA primarily functions as an acyl carrier molecule, through a thioester linkage
between the acyl group and the free thiol of CoASH (reduced CoA). There are numerous
CoA-derivatives, including a thioester for most individual fatty acids (a comprehensive
list is provided in the appendix, Table A.1). One important class of acyl-CoA species is
4
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Figure 1.2 Pantothenate and CoA biosynthesis. As illustrated here, plants, fungi and
many prokaryotes are capable of de novo pantothenate synthesis from valine and
aspartate, while other organisms require it as an essential nutrient. Pantothenate is
subsequently converted to CoA through the sequential action of five enzymes. CoA can
then be incorporated into various acyl-CoA thioesters. Previously published in Basu,
Blair. Nat Protocols, 2011.
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the short chain acyl-CoA thioester class, the measurement of which is the focus of this
thesis. Figure 1.3 illustrates the role of some of these compounds in relation to the Krebs
cycle. Of all short chain acyl-CoA species, acetyl-CoA is most prominent due its diverse
functions. Pyruvate formed by glycolysis is converted irreversibly by pyruvate
dehydrogenase into acetyl-CoA, which condenses with oxaloacetate to form citrate,
serving as a carbon entry point in the Krebs cycle. Each turn of the cycle produces
reducing equivalents in the form of NADH and FADH2, which are used in OXPHOS to
produce ATP (Figure 1.1). Another important CoA thioester is succinyl-CoA, a Krebs
cycle intermediate formed from α-ketoglutarate (aKG) by the action of aKG
dehydrogenase. Succinyl-CoA is then converted by succinyl-CoA synthetase into
succinate, which along with FADH2 is utilized by succinate dehydrogenase (complex II)
to reduce ubiquinone and generate fumarate (Figure 1.1). As compared to glycolysis, in
which a single glucose molecule can produce a net of 2 ATP, the coupled action of the
Krebs cycle and OXPHOS produces 36-38 ATP from a single molecule of glucose,
thereby providing a tremendous increase in energy efficiency. This improvement is
particularly striking in the case of β-oxidation of fatty acids (FAO). In FAO, fatty acids
which are often transported or stored as triglycerides are broken down through a
sequential process. In each cycle, the fatty acyl-CoA is shortened by two carbons, which
are released as acetyl-CoA and a new acyl-CoA thioester, two carbons shorter than the
original, is formed. The carbons from acetyl-CoA can then enter the Krebs cycle as
previously described, while the shortened acyl-CoA can undergo another round of
oxidation. The penultimate CoA thioester formed from even chained fatty acids is BHBCoA. The complete oxidation of a single palmitate molecule can provide 108 ATP. On
6
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Figure 1.3 Short chain acyl-CoA thioesters and the Krebs cycle. The structure of CoA
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Krebs cycle are illustrated.
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the other hand, acetyl-CoA can be converted to malonyl-CoA as the first step in fatty acyl
synthesis. In the case of odd chain fatty acids, the last acyl-CoA thioester is propionylCoA, which contains three carbons. This can subsequently enter the Krebs cycle through
succinyl-CoA. 3-hydroxymethyl-3-glutyryl-CoA (HMG-CoA) is another critically
important short chain acyl-CoA thioester involved in several metabolic pathways
including ketogenesis and cholesterol synthesis. In fact, HMG-CoA synthase is the rate
limiting enzyme of ketogenesis,38 a metabolic state in which ketone bodies are produced
by the liver to serve as alternative energy sources to glucose for the brain, and is induced
by starvation or high protein and low carbohydrate diets. HMG-CoA reductase is the rate
limiting enzyme in cholesterol synthesis and is the target of the widely prescribed statin
class of drugs (HMG-CoA reductase inhibitors).39 Although these are only a few of the
many CoA thioesters, we have primarily focused on these particular species due to their
critical importance in metabolism.
In addition to functioning as a fatty acyl-carrier, CoA is used in several other
capacities as well, including playing a prominent role in detoxification. One such role is
serving as a cofactor in phase II acetylation, where the acetate from acetyl-CoA is
activated and transferred to the metabolite. In fact, it was the acetylation properties of
CoA that led to its initial discovery by Fritz Lipmann in 1945,40 (the “A” in CoA was
used to represent “activation of acetate”).41 Also, like glutathione (GSH), CoASH can
react with xenobiotic compounds and electrophiles.42, 43 It has also been shown that
CoASH is the major reducing intracellular thiol in Staphylococcus Aureus, likely due to
the fact that these bacteria do not contain GSH.44 For this reason, along with the
structural elucidation of the enzymes in CoA synthesis,34 there has been a renewed
8

interest in this biosynthetic pathway for potential antimicrobial drug targets.33
Interestingly, the mixed disulfide glutathione-CoA (CoASSG) has also been shown to
form in vivo,45-48 though its exact role and mechanism of formation remains unclear.49-52
However, it has been shown that the ratio of CoASSG: CoASH is increased in settings of
mitochondrial oxidative stress such as hyperoxia53, 54 and seizures,55 indicating that like
GSSG:GSH ratio, which is used as a marker of cellular oxidative stress, CoASSG:
CoASH ratio may serve as an indicator of mitochondrial oxidative stress. Still, new roles
for CoA continue to be discovered, as is exemplified by the recent discovery of CoAlinked RNA adducts56 as well as CoA-electrophile adducts.43 The expansive roles of
CoA as well as studies showing that levels of CoA species are perturbed in many
pathological settings including diabetes,57, 58 as well as various inherited metabolic
disorders,59-64 has revitalized efforts to develop methods to measure these species.

1.3 Measuring CoA
Given that CoA-activated compounds can differ so dramatically in their chemical
properties, the class of CoA species to be measured must be considered first. These can
be broken down as follows: reduced CoA (CoASH), acyl-CoA thioesters, CoA-disulfides,
and other CoA-activated compounds, which may include a broad number of CoA adducts
bound to exogenous or endogenous electrophiles. Although there is a continuum in the
length of the carbon tails of acyl-CoA thioesters, these can be basically broken down into
short- (up to 5 carbons), medium- (up to 10 carbons), long- (up to 20 carbons) and very
long-chain (more than 20 carbons) acyl-CoA species. Due to differences in chemical and
physical properties of these different acyl-CoA species, different classes of CoA
9

derivatives require different extraction methods. In general, short chain acyl-CoA
species are acid soluble and if a biological sample is sonicated or homogenized in a
strong acid solution, the acid soluble short chain acyl-CoA species can be extracted.65, 66
This can be accomplished by using sulfosalicylic acid (SSA), perchloric acid or
trichloroacetic acid (TCA). In general, a 10% TCA solution was the most optimal for
short chain acyl-CoA extraction.67 After acid extraction, these short chain acyl-CoA
species can be further purified using solid phase extraction (SPE) or repeated ether
extraction to remove the TCA. SPE extraction was generally favorable for both ease and
cost factors.67 For medium, long and very long chain acyl-CoA molecules, performing a
liquid-liquid extraction with an organic solvent is ideal.68-70
Also, the source of CoA is important as well. CoA molecules can be measured
from whole cells (or tissues), or from isolated mitochondria. While the ability to isolate
and study viable mitochondria set the foundation for much of our understanding of
mitochondrial biology,71 the act of isolating mitochondria can generate oxidative stress
leading to artifactual changes attributed to sample processing.72 More importantly, when
developing biomarker studies to measure CoA changes, whole tissues or cells (such as
fibroblasts or blood cells) need to be extracted since CoA species are intracellular.
Further isolation of mitochondria from these cells would not only introduce oxidative
stress, but would also be laborious and clinically impractical. Therefore, whole cell
assays were the chosen method in our work.
Like mitochondria, the discovery of CoA also preceded the discovery of the
double helix. CoA was first described by Fritz Lipmann in 1945, for which he was
eventually awarded the Nobel Prize in Medicine in 1953.41 Over the next forty years, a
10

significant amount of research was focused on the identifying, separating and accurately
measuring acyl-CoA thioesters in biological systems. The majority of methods
developed through these decades focused on high performance (HP) liquid
chromatography (LC) coupled with ultraviolet (UV) detection.65, 66, 73 CoA species
exhibit a characteristic UV absorption at 254 nm. Since all CoA thioesters contain the
CoA moiety, they can be readily detected if properly separated. However, because UV
detection is used, complete baseline separation is required for measurement of CoA
species. To accomplish this for short-chain acyl-CoA species, high concentrations of
phosphate buffer were needed to successfully separate a broad number of these species.65
Additional LC-UV methods were also made for other CoA derivatives. One problem
with such methods is lack of specificity due to co-eluting peaks. More importantly,
however, even the best methods had a sensitivity which was generally in the high
picomolar to single-digit nanomolar range. While this may be adequate from larger
pieces of animal tissue containing abundant CoA species, this is inadequate for
practicable in vitro analysis or clinical studies involving much smaller amounts of
biological material. Over the next two decades, significant technogical improvements in
mass spectrometry (MS) have allowed not only increased specificity but also dramatic
improvements in sensitivity of CoA analysis. These LC-MS methods have been used in
the measurements of short chain acyl-CoA species,67, 74-76 as well as medium and long
chain acyl-CoA species.68-70 Although MS methodology has notable advantages in
sensitivity and specificity, it also can present variable precision and accuracy, especially
with electrospray ionization (ESI).77, 78 Stable isotope dilution mass spectrometry can be
used to overcome this problem.
11

1.4 Stable isotope dilution MS
LC-selected reaction monitoring (SRM)/MS provides a highly sensitive and
specific platform to measure a broad range of analytes in a variety of complex biological
matrices.79 In addition, advancements in high resolution mass MS80, 81 as well as the
development of more dynamic software platforms82-84 have provided scientists the
capability of measuring thousands of different analytes in a single run, making MS the
optimal methodology for robust high-throughput metabolomic and proteomic analyses.85,
86

Nonetheless, appropriate internal standards are critical for the success of any MS-

based method, particularly when measuring endogenous metabolites in biological
samples, due to matrix effects on analyte stability, extraction, and ionization efficiency.77,
78, 87-90

To account for these effects, an internal standard that faithfully reproduces the

biological and chemical properties of the analyte of interest is needed.91 Stable isotope
analogs represent the best internal standards for MS-based analyses because they have the
same biological and physicochemical properties as the analyte of interest, but can still be
distinguished by a mass spectrometer.91

1.5 Stable Isotope Labeling with Amino acids in Cell culture (SILAC)
Difficulty in chemically synthesizing stable isotope analogs of complex biological
molecules has spurred the development of techniques to generate these standards in
biological systems.92-94 In the case of proteins, a method called SILAC has been
developed (Figure 1.4).95 After generation of isotopically labeled cells, one of two
possible experimental modalities can be used. In the “classical” SILAC approach, an

12

[13C615N2]-Lysine

[13C615N2]-Leucine

[13C615N2]-Labeled
proteins
[13C615N2]-Labeled
peptides

Figure 1.4 Stable Isotope Labeling with Amino acids in Cell culture (SILAC). In this
method, cells are grown in the presence of a stable isotope-labeled essential amino acid
such as lysine or leucine, with the unlabeled form specifically omitted. The inability to
synthesize these essential amino acids de novo results in their exclusive uptake and
incorporation into cellular proteins. After serial passages in this media, greater than 99%
of these residues are labeled. These can then be used for stable isotope dilution MS.
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equal number of labeled and unlabeled cells are subjected to different stimuli, mixed,
processed together and analyzed by MS.95 Alternatively, the labeled cells can be lysed to
produce a stable isotope labeled proteome internal standard (SILAP),96 which can then be
spiked into different experimental samples to normalize the measured analytes for
relative quantitation.97-99 The advantage of the latter approach is the ability to apply these
standards to both in vitro or in vivo samples, as well as avoiding any biological
perturbations introduced by growing the cells in labeled amino acids.
Like proteins, CoA and other endogenous metabolites have been difficult to
chemically synthesize and consequently labeled analogs for many of these compounds
are not commercially available. In the following chapter, we present a novel methodology
to generate isotopically labeled CoA internal standards.

14

Chapter 2: The development of Stable Isotope Labeling by Essential Nutrients in
Cell Culture (SILEC) for preparation of labeled CoA and its thioesters

2.1 Abstract
While CoA and acyl-CoA thioester derivatives are central players in numerous
metabolic pathways, the lack of a commercially available isotopically labeled CoA limits
the development of rigorous stable isotope dilution MS-based methods. In this chapter,
we adapted SILAC methodology to biosynthetically generate stable isotope labeled CoA
and CoA-thioester analogs for use as internal standards in an LC-SRM/MS assay. This
was accomplished by incubating murine hepatoma cells (Hepa 1c1c7) in media in which
pantothenate, a CoA precursor, was replaced with [13C315N1]-pantothenate. Efficient
incorporation into various CoA species was optimized to > 99% [13C315N1]-pantothenate
labeling after three passages. Charcoal-dextran stripped FBS (csFBS) was found to be
optimal for serum supplementation due to its lower contaminating unlabeled pantothenate
content. In addition, a method to generate specific CoA derivatives was demonstrated by
treating SILEC- labeled cells with propionate to generate [13C315N1]-propionyl-CoA.
Labeled cells were harvested, and stable isotope labeled CoA species were extracted and
utilized as internal standards for CoA thioester analysis in cell culture as well as in mouse
tissue. This SILEC methodology can serve as a paradigm for using vitamins and other
essential nutrients to generate stable isotope standards that cannot be readily synthesized.

Portions of this chapter have been previously published (Basu et al. Anal Chem, 2011; Basu SS, Blair IA.
Nat Protocols, 2011).
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2.2 Introduction
CoA, a ubiquitous fatty acyl carrier plays a critical role in many metabolic and
mitochondrial processes.35, 100, 101 MS/MS represents the optimal platform for developing
CoA analysis due to its sensitivity and specificity. Also, when subjected to collisioninduced dissociation (CID), CoA derivatives exhibit a characteristic fragmentation
pattern, breaking at the ATP moiety, resulting in product ions with a neutral loss of 507
amu (Figure 2.1A).76, 102 Typical parent protonated molecular ions observed for
endogenous CoASH and its derivatives in a constant neutral loss/MS experiment are
presented in Figure 2.1B. The use of this type of analysis not only facilitates LCSRM/MS method development, but also allows for more specific CoA discovery
experiments. However, the lack of isotopically labeled CoA has limited the development
of comprehensive stable isotope dilution MS/MS analysis of CoA-containing compounds.
In this chapter, our focus is in generating stable isotope labeled CoASH and shortchain acyl-CoA species, which would not only improve our ability to study metabolism,53,
54, 58, 103

but also aid in the diagnosis of various metabolic diseases.60-64, 104 The use of

labeled standards is particularly important, since cellular thiols can be rapidly oxidized or
react with both intracellular and extracellular molecules.105-107 To biosynthetically
generate labeled CoA standards, we developed SILEC, a method similar to SILAC,
except that a labeled vitamin, pantothenate, is used instead of labeled amino acids.93
Unlike plants, fungi, and most prokaryotes, animals are not capable of de novo
pantothenate synthesis.33 As a result, pantothenate is a dietary requirement and a
necessary cell culture media supplement. After uptake, pantothenate is converted to CoA
through five enzymatic steps.35 By growing cells in the presence of [13C315N]16
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Figure 2.1 CoA structure and LC-constant neutral loss/MS analysis. (A) Generalized
CoA structure, showing the CID-induced neutral loss of the ATP moiety (m/z 507). The
substituent (R group) can include any thioester or derivative of CoA arising from
endogenous or exogenous sources. (B) LC-constant neutral loss/MS scans (m/z 507) of
short chain acyl-CoA species extracted from unlabeled Hepa 1c1c7 murine hepatoma
cells. The extraction was performed as described in the methods section. The precursor
parent molecules of various short-chain acyl-CoA species are annotated in the spectrum.
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pantothenate, the stable isotopes were incorporated into CoA (Figure 2.2) much as
labeled lysine and leucine are incorporated into proteins using SILAC methodology.
This allowed us not only to generate isotopically labeled CoASH, but also a wide variety
of acyl-CoA thioesters in a single biological system. In this chapter, we present the
development of this method, with particular focus on optimization of growth conditions,
scale-up, validation as well as preparation of specific CoA species, which were
subsequently extracted and used as LC-MS internal standards in vitro as well as in mouse
tissue. A detailed step-by-step protocol and troubleshooting guidelines are presented in
the following chapter.

2.3 Materials and Methods
2.3.1 Chemicals and Reagents.
CoASH, acetyl-CoA, succinyl-CoA, HMG-CoA, propionyl-CoA, SSA, TCA and
menadione were purchased from Sigma Aldrich (St. Louis, MO). RPMI 1640
pantothenate-omitted media was purchased from AthenaES (Baltimore, MD).
Undialyzed FBS (uFBS), dialyzed FBS (dFBS), and charcoal-dextran stripped FBS
(csFBS) were purchased from Gemini Bio-Products (West Sacramento, CA). All
solvents used were Optima grade (Fisher Scientific, Pittsburgh, PA). [13C315N1]pantothenate was purchased from IsoSciences (King of Prussia, PA).
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Figure 2.2 Incorporation of [13C315N1]-pantothenate into CoA. Enzymes: (A)
Pantothenate kinase (rate-determining). (B) Phosphopantothenoyl cysteine synthetase.
(C) Phosphopantothenoyl cysteine decarboxylase. (D) Phosphopantetheine
adenylyltransferase. (E) Dephospho-CoA kinase. [13C] and [15N] atoms are marked in
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2.3.2 Cell culture and extraction of short chain CoA thioesters.
Murine hepatocytes (Hepa 1c1c7, ATCC #CRL-2026) were maintained in RPMI
1640 media supplemented with 10% FBS, 2 mM L-glutamine, 100 units/mL penicillin
and 100 µg/mL streptomycin at 37°C and 5% CO2. Extraction of CoA species was
performed using modifications to similar methods.102, 108 Briefly, cells were washed twice
with 10 mL of ice cold PBS. Cells were harvested by scraping into 1 mL of PBS. A 100
µL aliquot was saved for protein quantitation and the remainder was pelleted at 1000g.
The cell pellet was resuspended in 1 mL ice cold 10% TCA and pulse-sonicated for 30
sec on ice using a sonic dismembranator (Fisher), followed by a 5 min centrifugation at
15000g. The supernatant was transferred to a fresh tube and the pellet was discarded.
The supernatant was purified by SPE as follows: Oasis HLB 1cc (30 mg) SPE columns
(Waters) were pre-conditioned with 1 mL methanol followed by equilibration with 1 mL
water. The collected supernatant was applied, washed with 1 mL water and finally eluted
using 3 subsequent applications of 0.5 mL methanol containing 25 mM ammonium
acetate. Eluted compounds were dried down with nitrogen and resuspended in 100 µL
5% 5-SSA. Injections of 10 µL were made for LC-MS analysis.

2.3.3 LC-MS.
Analytes were separated using a reversed phase Phenomenex HPLC Luna C18
column (2.0 x 150 mm, pore size 5 µm) with 5 mM ammonium acetate in water as
solvent A, 5 mM ammonium acetate in 95/5 acetonitrile/water (v/v) as solvent B and
80/20/0.1 (v/v/v) acetonitrile/water/formic acid as Solvent C. Gradient conditions were
as follows: 2% B for 1.5 min, increased to 25% over 3.5 min, increased to 100% B in 0.5
20

min and held for 8.5 min, washed with 100% C for 5 min, before equilibration for 5 min.
The flow rate was 200 µL/min. Samples were analyzed using an API 4000 triple
quadrupole mass spectrometer (Applied Biosystems, Foster City, CA) in the positive ESI
mode. Samples (10 µL) were injected using a Leap CTC autosampler (CTC Analytics,
Switzerland) where they were maintained at 4°C, and data was analyzed with Analyst
1.4.1 software. The column effluent was diverted to the mass spectrometer from 8 min to
13 min and to waste for the remainder of the run. The mass spectrometer operating
conditions were as follows: ion spray voltage (5.0 kV), compressed air as curtain gas (15
psi) and nitrogen as nebulizing gas (8 psi), heater (15 psi), and collision-induced
dissociation (CID) gas (5 psi). The ESI probe temperature was 450°C, the declustering
potential was 105 V, the entrance potential was 10 V, the collision energy was 45 eV, and
the collision exit potential was 15 V. Isotopic labeling using [13C315N1]-pantothenate
resulted in labeled CoA and thioester derivatives with a mass shift of 4 amu. Transitions
employed for LC-SRM/MS analyses are shown in Table 2.1.

2.3.4 Stable isotope labeling using [13C315N1]-pantothenate.
Labeling of CoA and its thioesters was achieved using a procedure similar to
SILAC except that [13C315N1]-pantothenate was used instead of labeled amino acids.92
Murine hepatocytes were cultured in RPMI media containing 1 mg/L [13C315N1]pantothenate and 10% serum (uFBS, dFBS, or csFBS). To monitor labeling efficiency,
cells were harvested at each passage and processed as described above. The ratio of
unlabeled to labeled CoASH was used to monitor labeling and to calculate absolute
concentrations of pantothenate. To characterize pantothenate labeling, cells were grown
21

Compound
CoASH

Parent Daughter
(m/z)
(m/z)
768.1

261.1

[ C3 N1]-CoASH

15

772.1

265.1

Acetyl-CoA

810.1

303.1

[ C3 N1]-Acetyl-CoA

15

814.1

307.1

Propionyl-CoA

824.1

317.1

[13C315N1]-Propionyl-CoA

828.1

321.1

Succinyl-CoA

868.1

361.1

[13C315N1]-Succinyl-CoA

872.1

365.1

HMG-CoA

912.1

405.1

15

916.1

409.1

13

13

13

[ C3 N1]-HMG-CoA

Table 2.1 SRM transitions for short-chain CoA thioesters and stable isotope labeled
analogues prepared by SILEC.
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to confluence, washed and treated with the labeling media for 0, 1, 3, 6, 12, 18 or 24 h,
followed by harvesting and extraction. CoA labeling and scale-up were optimized by
varying the type of serum (uFBS, dFBS and csFBS) as well as the concentration of
[13C315N1]-pantothenate, supplemented into the labeling media. After scale-up (as
described below), cells were harvested by scraping and sonication in 10% TCA.
Acidified extracts containing stable isotope labeled CoA thioesters were pooled,
aliquoted, frozen, stored at -80°C and thawed as needed.

2.3.5 Scale up of labeled CoA standards
Cells were split 1:5, collected, and processed each day for seven days. Although
there was some minor variation among different CoA species, the peak level for each of
the CoA species occurred on day 4 or 5 (appendix, Table A.2). Therefore, a two-step
approach was employed. First, cells were grown in media supplemented with 10%
csFBS and 1 mg/L [13C315N1]-pantothenate for three passages. Second, the media was
replaced on the third day of the final passage with media containing 3 mg/L [13C315N1]pantothenate and 3% csFBS. The incubation was continued overnight; cells were then
harvested and processed the next day. This resulted in efficient labeling of all CoA
species to > 99.5% labeling. Typically this was conducted using twenty plates or more.

2.3.6 Validation.
Cells from twenty plates were sonicated in 10% TCA (0.5 mL per plate), pooled
and aliquoted into 3 fractions of 3 mL, which were subsequently stored at -80°C. Lysates
from [13C315N1]-pantothenate-labeled cells were prepared as described above and also
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stored at -80°C. CoASH and short chain acyl-CoA standards were also stored in 5% SSA
at -80°C. For the standard curve, CoA standards were thawed and diluted using 10%
TCA, each with a final volume of 0.5 mL. One 3 mL cell lysate aliquot was thawed each
day of the validation and divided into six 0.5 mL aliquots. Each of the standards as well
as the fractions was mixed with 0.5 mL of the labeled CoA TCA lysate. Samples were
processed as described above. Intra-day and inter-day validation was performed for each
analyte.

2.3.7 Application of SILEC standards to cell culture using propionate treatment
Propionate incorporation into propionyl-CoA in Hepa 1c1c7 cells was used as a
model for CoA metabolism.109 Treatments were performed in 10 cm tissue culture dishes
and cells were grown to 90% confluence and washed twice with PBS prior to treatment.
Cells were treated in a minimal treatment media consisting of HBSS, supplemented with
CaCl2, MgSO4, glucose and 25 mM HEPES buffer. Propionate stocks were prepared in
HBSS at 1 M and diluted to a final treatment concentration of 10 mM. Control cells were
treated with treatment media alone. Cells were treated for 1 h and processed as described
above. Due to the wide disparity of CoA thioesters concentrations in treated compared
with untreated cells, an optimal “customized” internal standard mixture was generated by
combining the CoA extracts from untreated SILEC cells and an equal number of
propionate-treated SILEC cells. This internal standard contained an acyl-CoA profile
more applicable to both experimental groups. An equal amount of these extracts were
added into both groups as well as the standard curve. Experimental cells were
maintained as described previously.
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2.3.8 Application of SILEC standards to mouse tissues
Snap frozen mouse livers were obtained from the Lazar lab. Liver sections (30100 mg) from either fed or fasted (12 h) mice were stored at -80°C. 0.8 mL ice cold 10%
TCA was added to each tube along with 0.2 mL SILEC standards. Samples were
homogenized twice using a Tissuelyzer system (Qiagen) at 30 Hz, for 3 minutes, and
subsequently centrifuged at 21000g to precipitate protein pellet. The acid extract was
then purified using Oasis HLB SPE columns as previously described, except two washes
with water were performed. Standard curve samples were processed in a similar fashion.

2.4 Results and Discussion
2.4.1 LC-SRM/MS and CoA extraction.
While multiple LC-MS methods have been developed to analyze CoA thioester
species in plant74, 110 and animal tissues,70, 102 the focus of our study is using mammalian
cell culture models, which often require increased sensitivity.75, 111 CoA and short chain
CoA thioesters were identified in cellular extracts using a constant neutral loss scan of
m/z 507 amu corresponding to ATP (Figure 2.1). SRM transitions were developed for
five unlabeled and labeled CoA thioesters (Table 2.1) in order conduct sensitive
quantitative LC-MS analysis. However, the SILEC technique can be readily extended to
any short, medium, or long chain acyl-CoA thioester by modifying the extraction
procedure.112 Due to the similarity of the various short-chain CoA thioesters, LCSRM/MS analysis was employed for specific identification as well accurate and precise
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quantification of the various CoA species without requiring absolute baseline separation
as is required in HPLC-UV methods.66, 113 CoA standards and acid extracted acyl-CoA
molecules from hepatocytes were separated and quantified using LC-SRM/MS (Figure
2.3).

2.4.2 Stable isotope labeling with [13C315N1]-pantothenate.
Stable isotope labeled CoA thioester derivatives were generated by growing cells
in pantothenate-omitted media supplemented with [13C315N1]-pantothenate. To verify and
characterize the incorporation of labeled pantothenate into acyl-CoA species, cells were
grown in labeled media, harvested at different times, and processed (Figure 2.4). Various
CoA species and their heavy labeled isotopes were monitored to assess the relative
amounts of labeling. The ratio of labeled to unlabeled CoA was consistent throughout all
analyzed CoA thioesters. Labeled CoASH could be detected as early as 3 h, replacing
approximately 4% of the CoASH in the cells every hour. After 12 h, there appeared to be
a labeling “plateau”, likely the result of an active or sequestered CoA pool unavailable
for turnover.
Like SILAC methodology, labeling efficiency is dependent on the relative
concentration of labeled to unlabeled substrate in the media. As such, minimizing
unlabeled pantothenate in the media is critical for the production of pure isotopically
labeled CoA standards. Since circulating vitamins represent a major source of
contaminating unlabeled pantothenate in serum-supplemented cell culture, three different
types of sera were tested: undialyzed (uFBS), dialyzed (dFBS) and charcoal-dextran
stripped (csFBS). Although dFBS and csFBS are both often used in many cell culture
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Figure 2.3 LC-SRM/MS chromatograms of short chain acyl-CoA thioesters. (A) CoA
thioester standards (1 pmol each) and (B) acid extracted and SPE purified CoA species
from Hepa 1c1c7 cells.
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Figure 2.4 Stable isotope labeling of CoA thioesters in Hepa 1c1c7 cells grown in
[13C315N1]-pantothenate (1 mg/L). (A) LC-constant neutral loss/MS analysis with a
neutral loss of m/z 507 from hepatocytes extracts after 24 h of pantothenate labeling. (B)
Time course (24 h) of pantothenate incorporation into CoA.
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applications to decrease inter-batch variation, dialysis uses only size filtration, while
stripping serum with activated charcoal more specifically binds and depletes certain small
molecules such as steroids,114 peptide hormones, and vitamins.115 We found that maximal
labeling was achieved by the third passage with minimal increases in labeling with
additional passages (Table 2.2). csFBS was determined to be the most efficient for our
application due to its lower pantothenate content. The maximal achievable steady-state
of labeled CoA represents the percentage of labeled pantothenate to total pantothenate in
the media. By determining the percentage of CoA that is labeled within the cells, the
concentration of unlabeled contaminating pantothenate was calculated and determined:
uFBS (5.8mg/L), dFBS (0.21 mg/L) and csFBS (0.091mg/L) (Table 2.3).

2.4.3 Scale up and customization of stable isotope labeling of CoA and its thioesters.
To increase the purity of the labeled CoA standards, two techniques were
employed: (A) increasing the amount of [13C315N1]-pantothenate in the media, or (B)
decreasing the amount of serum. Decreasing the serum concentration resulted in
significantly slowed growth characteristics, while further increases in media
supplementation of [13C315N1]-pantothenate resulted in limiting returns on labeling. By
utilizing a two-step approach using 10% csFBS initially followed by a final incubation
with 3% csFBS, efficient scale-up was achieved while limiting the amount of labeled
pantothenate that was required. A chromatogram demonstrating isotopically pure CoA
internal standards is provided in the appendix (Figure A.1). To generate more of a
particular labeled CoA thioester internal standard, we treated SILEC labeled cells with 10
mM propionate for 1 h. After incubation these cells were harvested and processed for
29

Passage #
1

2

3

4

5

Serum

uFBS 59.3 59.8 55.9 58.7 63.4
dFBS 93.5 97.6 97.7 97.4 97.9
csFBS 94.6 98.4 98.9 99.0 99.1

Table 2.2 Effect of different sera on stable isotope labeling of CoA (above) and
determination of unlabeled pantothenate content in supplemented sera. Percentage of
labeled CoASH in Hepa 1c1c7 cells serially passaged in pantothenate-omitted RPMI
1640 media supplemented with 1mg/L [13C315N1]-pantothenate and 10% serum: uFBS,
dFBS, csFBS.

%Lmax = fraction of labeled CoA (max), experimentally determined (Table 2.2)
L = labeled supplemental pantothenate (1 mg/L)
U = unlabeled pantothenate (mg/L)
1
U
L
1


% L max =

 U = L *
= 1+
− 1
+
L U
% L max
L
 % L max 

%Lmax
uFBS
dFBS
csFBS

63.4%
97.9%
99.1%

L
(mg/L media)
1.0
1.0
1.0

U
(mg/L media)
0.58
0.021
0.0091

U
(mg/L serum)
5.8
0.21
0.091

Table 2.3 Determination of unlabeled pantothenate in different batches of FBS and in the
cell culture media prepared from them.
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CoA thioesters. We found that there was a substantial increase in the amount of
[13C315N1]-propionyl-CoA in these cells (Figure 2.5)
Other approaches to generating heavy labeled CoA species are possible, though
less optimal. Since CoA contains pantothenate, cysteine, and ATP, labeling with cysteine
or a heavy labeled carbon source, would also result in labeled CoA. One limitation of
cysteine labeling is that this can be synthesized de novo, which would result in decreased
isotopic purity of the compound. Furthermore, since only a small fraction of cysteine or
carbon from isotopic nutrient sources are incorporated into CoA, these methods are less
efficient than the described method, where nearly all of the pantothenate is incorporated
into CoA. Furthermore, preparation of [13C315N1]-analogs avoids problems that can arise
through the metabolic instability of deuterium and the separation of deuterium and
protium analogs that occurs during LC-MS analysis.116 Finally, methods using stable
isotope CoA compounds with labeled acyl moieties are limited to those in which such
labeled thioesters are available.108 If a large number of CoA species are quantified, this
would require labor-intensive preparation of each standard individually. Also, labeled
CoASH could not be produced using this methodology. In contrast, biosynthetic
generation of CoA thioesters provides simultaneous synthesis of every labeled thioester
standard in a particular cell type in a naturally occurring profile in the appropriate
concentration range to be used in the study. Moreover, different internal standard
mixtures could be readily generated for specific applications by treating the labeled cells
with a precursor fatty acid to reflect more appropriate thioester concentrations (Figure
2.5).
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Figure 2.5 Preparation of a specific stable isotope labeled CoA thioester stable isotope
standard. CoA extracts from stable isotope labeled cells (A) untreated and (B) treated
with 10 mM propionate for 60 min.
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2.4.4 Assay validation.
Validation was performed on various CoA thioesters using our SILEC-derived
internal standards (Table 2.4). Extracted samples were quantified with and without
SILEC standards. Specificity was also improved since the compounds were co-eluting
with their standards. More importantly, it was found that using stable isotope analogs as
internal standards provided a significant improvement in accuracy and precision when
compared with non-identical internal standards (appendix, Table A.3). The approach
more commonly employed involves using a non-labeled compound that is similar, but
distinct, from the analyte of interest as the internal standard. There are several drawbacks
to using this type of method. First, using an internal standard that is different than the
analyte of interest presumes that both analyte and internal standard will behave equally
throughout the assay. While this may be a reasonable assumption for closely related
compounds, as compounds diverge chemically, they also will show a greater disparity in
their behavior. Second, ESI is particularly susceptible to matrix effects, due to the
limited amount of ionization that can occur at the source. These effects can lead to an
under- or overestimation of certain compounds as they co-elute in a complex mixture.77,
78, 90

Matrix effects are non-linear and can vary dramatically throughout a gradient run,

particularly when analyzing tissue samples. Finally, analyte stability and loss during
sample preparation can vary considerably for different CoA species. Therefore, the
assumption that the measured analyte will have the same stability as the analog internal
standard may also lead to over- or underestimation of the compound. Additionally, the
stable isotope can act as a carrier for trace analytes and improve sensitivity.
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Linearity Precision (RSD) LOQ
(R )

Intrabatch

Inter(pmol)
batch

Acetyl-CoA

0.9990

2.4%

2.6%

0.1

Succinyl-CoA

0.9996

5.6%

1.6%

0.2

CoASH

0.9966

6.8%

2.6%

0.1

Propionyl-CoA

0.9999

9.1%

13.9%

0.05

HMG-CoA

0.9939

7.1%

10.4%

0.2

2

Table 2.4 Assay validation. Standard curves were generated by spiking increasing
concentrations of different CoA standards with 0.5 ml of acid extracted CoA. Pooled
frozen extracts from Hepa cells were thawed and mixed with internal standard mixture
and extracted. Limit of quantitation (LOQ) was determined to be the level at which the
signal-to-noise ratio was at least 5:1 compared to a blank.
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2.4.5 Applications of SILEC standards to biological samples
Cells treated with 10 mM propionate for 1 h showed a 10-fold increase in
propionyl-CoA levels as compared to control cells, with concomitant decreases in levels
of acetyl-CoA, succinyl-CoA, and CoA (Figure 2.6). In addition to cell culture, SILEC
internal standards improved the precision of CoA measurements from tissues as well.
Livers from fasted vs. fed mice showed significant differences in various short chain
acyl-CoA species. In particular, there was a significant decrease in the amount of acetylCoA and succinyl-CoA levels, and an increase in the propionyl-CoA levels. There was
also an increase in CoASH, though this change was not statistically significant. These
data are consistent with a recently published study in fed and fasted mice, except that
acetyl-CoA levels were increased rather than decreased in their model. However,
differences in diet, fasting conditions as well as mouse line may contribute to the
differences between these studies.

2.5 Conclusions
A SILEC method has been developed for generating labeled CoA and CoA
thioester standards by adapting SILAC methodology to utilize an essential vitamin and an
endogenous biosynthetic pathway. Isotopically labeled substrates have been employed
previously in tracer experiments to monitor cellular metabolic flux.94 However, our study
has focused on the optimization and scale-up of stable isotope labeled standards with low
levels of the endogenous unlabeled analogs for use in quantitative assays. By using
csFBS instead of dFBS or uFBS, more effective incorporation of pantothenate was
achieved. The resulting SILEC methodology employing [13C315N1]-pantothenate
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Figure 2.6 Changes in intracellular CoA thioester levels in Hepa 1c1c7 after propionate
treatment: untreated (white), 10 mM propionate for 1 h (black). CoA thioesters extracted
from control and treated SILEC-labeled cells were combined and used as stable isotope
internal standards in measuring short chain acyl-CoA species. * p<0.005

Acetyl-CoA
Succinyl-CoA
CoASH
Propionyl-CoA
HMG-CoA

Fed
26.1
9.2
75.5
0.19
0.41

Fasted
12.8
5.3
95.3
0.33
0.13

p value
2.E-04
5.E-04
0.43
0.02
3.E-06

Table 2.5 CoA-thioester levels in fed vs. fasting mice. Frozen mouse livers were
processed for CoA levels using SILEC standards, n = 5 per group.
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(instead of labeled amino acids used in SILAC methodology) made it possible to
rigorously quantify short chain CoA thioesters in cell culture.
While our analysis was limited to short chain acyl-CoA species, this approach
could be readily adapted to analyze medium or long chain CoA thioesters and other CoAcontaining species with minor modifications to the extraction protocol.112 Furthermore,
by adapting the SILEC methodology, it could also be used to synthesize stable isotopes
for metabolites that are derived from other isotopically labeled essential nutrients such as
folates, riboflavin (vitamin B2), and niacin (vitamin B3). Stable isotope labeled
metabolites from the extracts of these cells could subsequently be used as internal
standards to more accurately quantify folate polyglutamates,117 NAD,118 or FAD.119
Finally, the availability of labeled CoASH will facilitate the development of methodology
for the quantification of this important mitochondrial thiol and its oxidized mixed
disulfide derivatives such as glutathione-CoA.
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Chapter 3: A practical protocol for the generation and application of SILEC mass
spectrometry standards to biological samples

3.1 Abstract
SILEC was developed in Chapter 2 to generate isotopically labeled CoA and
short-chain acyl-CoA thioesters, by modifying SILAC to include [13C315N1]-pantothenate
instead of the isotopically labeled amino acids. The lack of a de novo pantothenate
synthesis pathway allowed for efficient and near-complete labeling of the measured CoA
species. This chapter provides a step-by-step approach to generating SILEC labeled
internal standards in mammalian and insect cells, as well as how to utilize them in stable
isotope dilution MS-based analyses. Troubleshooting guidelines as well as a list of
unlabeled and labeled CoA species are also included. This protocol represents a
prototype for generating stable isotope internal standards from labeled essential nutrients
such as pantothenate.

Portions of this chapter have been previously published (Basu SS, Blair IA. Nat Protocols, 2011).
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3.2 Overview
SILEC methodology can be used to label CoA in any cell system that does not
contain a robust de novo pantothenate synthesis pathway, including mammalian and
insect cell lines, both of which are described in this protocol. Hepa 1c1c7 murine
hepatoma cells were originally chosen due to their rapid growth rates in SILEC media,
the abundance of short-chain acyl-CoA species of interest, and relative ease in scalability.
In this chapter, we increase the breadth of the method developed in Chapter 2 by adapting
SILEC labeling to Drosophila S2 cells, which have even shorter doubling times and grow
in suspension, facilitating larger scale preparations of labeled standards. The purpose of
this protocol is to provide a practical guide to generate stable isotope labeled short-chain
acyl-CoA thioesters for use as internal standards in quantitative stable isotope dilution
LC-MS assays.

3.2.1 Generation of labeled CoA
Biosynthetic generation of labeled CoA standards can be divided into four steps
(Figure 3.1). The objective of the first step is to label the majority of the intracellular
CoA while still generating enough cellular material to accommodate the proposed
experiment. To accomplish this, cells are passaged 3-5 times in media containing 10%
csFBS and 1mg/L [13C315N]-pantothenate, with unlabeled pantothenate specifically
omitted. By the third passage, approximately 98-99% of the CoA in the cell are
isotopically labeled. In the second step, the media is replaced overnight with ultralabeling media containing a higher concentration of labeled pantothenate (2-3 mg/L) and
a lower concentration of serum (0-5%). This both increases the concentration of labeled
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Generation of SILEC internal
standards
[13C 3 15N]-pantothenate

Application of SILEC internal
standards
5. Spike-in SILEC internal standards

Standards

Experimental

Control

1. Expansion
(Labeling)

6. Sample processing
2. Ultra-labeling

3. Customization

7. LC/MS Analysis

Unlabeled CoA species

4. Extraction of
customized
SILEC internal
standards
Peak area (unlabeled )
Peak area (labeled)

Labeled SILEC internal standards
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5
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Control

Experi mental
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Figure 3.1 General scheme for Stable Isotope Labeling by Essential nutrients in Cell
Culture (SILEC). (1) Expansion. Cells are serially passaged and expanded in the
presence of labeled pantothenate. (2) Ultra-labeling. Media containing less serum and
more labeled pantothenate is used to increase purity of labeled CoA. (3) Customization
(optional). Labeled cells are subjected to different biological, pharmaceutical or
toxicological exposures to modify the CoA derivative profile within the cells. (4)
Extraction. Cells are lysed and pooled together to generate a SILEC CoA internal
standard mix with a more global CoA profile. (5) SILEC spike-in. Equal amounts of
SILEC internal standards are spiked into CoA standards, as well as in vitro, tissue or
clinical samples. (6) Sample extraction. Standards and samples are subjected to the same
sample extraction procedures. (7) LC-MS analysis. CoA species are separated and
analyzed by LC-SRM/MS. Co-eluting SILEC standards are used to confirm the identity
and normalize for the different CoA species.
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pantothenate in the media, while decreasing the level of the contaminating unlabeled
pantothenate from the serum. While serum-free culture could further decrease unlabeled
pantothenate levels, such conditions can also negatively affect growth, viability and
metabolic characteristics of cells in culture.120-122 Therefore, an optimal level of serum
must be determined to balance the benefits of increased labeling, while still maintaining
cellular characteristics. At this point, the CoA species from a representative plate can be
sampled to determine labeling efficiency and CoA profile using LC-neutral loss scan of
m/z 507. If the desired CoA species can be identified and measured, the third step is not
necessary. However, if one or more of the labeled CoA species of interest are below a
reproducibly quantifiable level, a customization step may be necessary. This can be
accomplished in multiple ways. First, labeled cells can be supplemented with a particular
fatty acid, such as propionate or β-hydroxybutyrate (BHB) which is then taken up by the
labeled cells to generate a higher percentage of that particular fatty acyl-CoA (Figure 3.2).
In addition, cells can be subjected to different biological perturbations or toxicological
insults to increase and decrease particular CoA species or to generate xenobiotic-CoA
adducts such as menadione-CoA (Figure 3.3). The CoA species in these cells can then be
extracted and pooled together to generate a SILEC reference metabolome, containing a
more appropriate or more global CoA profile for the experiment. Alternatively, the
cellular lysate can be hydrolyzed with a strong base, and the resulting [13C315N1]-CoASH
can be generated. This can be further purified and used to synthesize a particular CoA
derivative.73, 123-125
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(A)

(B)

(C)

(D)

(E)

(F)

Figure 3.2 SILEC labeling and “customization” of CoA metabolome. (A-C) LC-neutral
loss/MS scans (m/z 507) of acid extracted acyl-CoA species in SILEC-labeled Hepa
1c1c7 cells that were: (A) untreated, (B) treated with 10mM propionate for 1 h, or (C)
treated with 10 mM BHB for 1 h. (D-F) LC-neutral loss/MS scans (m/z 507) of acid
extracted acyl-CoA species in Drosophila S2 cells that were: (D) untreated, (E) treated
with 10 mM propionate for 1 h, or (F) treated with 10 mM BHB for 1 h. The precursor
ion masses of various labeled short chain acyl-CoA species can be identified: [13C315N]acetyl-CoA (m/z 814), [13C315N]-succinyl-CoA (m/z 872), [13C315N]-CoASH (m/z 772),
[13C315N]-propionyl-CoA (m/z 828), [13C315N]-BHB-CoA (m/z 858). These “customized”
CoA extracts can be pooled together to generate a more comprehensive CoA profile.
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(A)

[13C315N]MenadioneCoA O

CoA
O

(B)
m/z 942  435

Figure 3.3 Biosynthetic generation of isotopically labeled menadione-CoA. (A) LCneutral loss/MS scan (m/z 507) of acid-extracted CoA species from SILEC-labeled Hepa
1c1c7 cells treated with 20 µM menadione for 1 h. (B) LC-SRM/MS chromatogram of
[13C315N]-menadione-CoA (m/z 942  435) derived from the same extract. Extraction
and analysis were performed as specified. By spiking this extract into experimental
samples, this isotopically labeled analyte can be used as an internal standard for
quantifying unlabeled menadione-CoA.
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3.2.2 Application of SILEC standards to biological samples
The cellular extracts containing the SILEC-labeled CoA internal standards can be
applied to biological samples and used to normalize for the CoA species of interest
(Figure 3.1). These biological samples can include cultured cells, tissue samples, or
clinical samples of obtainable cells such as fibroblasts, lymphocytes or platelets. In each
case, a constant amount of SILEC standards are spiked into the samples at an early point
during sample processing; to scraped cells for in vitro experiments, to snap-frozen or
lyophilized tissues for in vivo experiments or into purified cells such as lymphocytes or
platelets for clinical studies. In addition to spiking the samples, the same amount of
SILEC-labeled CoA internal standards are also spiked into known quantities of unlabeled
CoA standards to generate a standard curve. Both biological samples and unlabeled CoA
standards can then be extracted using SPE and analyzed by LC-MS. The peak area of
each unlabeled standard is divided by the peak area of the corresponding SILEC internal
standard analog to generate a standard curve of standards to peak area ratio. The same
analysis is then performed on each sample and the peak area ratio is then used to
calculate the amount of each of the CoA species in the sample. These amounts are then
compared between experimental groups. This method is comparable to the SILAP or
SILAC “spike-in” methods that have been described previously.97, 99 The strength of
using a stable isotope dilution MS method is not only in the specificity of CoA elution,
but also that the labeled compounds will have the same stability as the unlabeled analyte
of interest. Therefore, there would be a parallel degradation of the labeled internal
standard that does not affect the ratio of unlabeled analyte to labeled internal standard.
For this reason, absolute quantification of the labeled internal standards is unnecessary.
44

3.2.3 Additional considerations for modifying SILEC approach
Although this protocol specifically addresses the ability to generate isotopically
labeled short chain acyl-CoA species, this can be modified to include other CoA species
or adapted for other essential nutrients. There are several general aspects to consider if
such an approach is taken. First, limitations of the SILEC approach are similar to those
encountered with SILAC labeling in that a biological system is used to generate stable
isotope standards. Although numerous labeled CoA species can be generated in a single
system, batch-to batch variability persists even under well-controlled conditions. If using
a starting material other than pantothenate such as folates, it is important to use media
and the appropriate serum that does not contain that essential nutrient. Therefore, an
omitted media along with a modified serum (such as csFBS or dFBS) is critical to
generating isotopically pure standard. Finally, finding the appropriate cell line is also
necessary for optimization. Since this is largely empirical, many cell lines likely need to
be tested to optimize scale-up and production. A time-course should be established in
order to determine the optimal time for harvesting from the chosen cell line, as was
demonstrated in the Chapter 2.

3.3 Materials
•

Cell line of choice (protocol written for Hepa 1c1c7 cells, ATCC #: CRL-2026
and Drosophila Schneider 2 cells, Invitrogen)

•

Media:
•

Mammalian cells: pantothenate-omitted RPMI 1640 media (AthenaES, MD)

•

Insect cells: Schneider’s media
45

•

Hank’s Buffered Salt Solution (HBSS)

•

Phosphate-buffered saline (PBS)

•

[13C315N1]-pantothenate (Isosciences, PA)

•

Charcoal-dextran stripped FBS (Gemini Biosciences, CA)

•

10 cm tissue culture dishes

•

75-cm2 tissue culture flasks

•

Cell scrapers

•

Penicillin, streptomycin

•

Glutamine

•

Trichloroacetic acid (TCA)

•

5-Sulfosalicyilic acid (SSA)

•

Potassium hydroxide (KOH)

•

Oasis HLB 1cc (30 mg) SPE columns (Waters)

•

10 mL conical glass centrifugation tubes

•

Nitrogen gas

•

Methanol

•

Ammonium acetate

•

Acetonitrile and water (mass spectrometry grade)

•

Formic acid

Instrumentation:
•

Probe sonicator

•

Microcentrifuge

•

Vacuum manifold
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•

Nitrogen evaporator

•

Refrigerated autosampler

•

HPLC system with three pumps

•

Triple quadrupole mass spectrometer (API 4000 or instrument of similar
sensitivity)

•

Computer with mass spectral computational software

Reagent Setup:
•

Heat-inactivated csFBS. Thaw at 37°C and heat inactivate complement for 30
min at 55°C. Aliquot into 50 mL fractions and store at -20°C.

•

[13C315N]-Pantothenate stocks. Prepare in double distilled (dd) H2O at 1 mg/mL
and store at -20°C.

•

Unlabeled CoA standards. Prepare 5 mM stock solutions of acyl-CoA species in
5% aqueous SSA. Store in aliquots at -80°C. Thaw when needed and avoid
repetitive freeze thaw cycles.

•

SILEC Expansion media. Mammalian cells: Prepare pantothenate-free media
containing 10% heat-inactivated csFBS, 2 mM L-glutamine, 100 I.U./ml
penicillin, 100 µg/ml streptomycin and 1 mg/L [13C315N]-pantothenate. Insect
cells (S2): Prepare Schneider’s media containing 10% heat-inactivated csFBS, 2
mM L-glutamine, 100 I.U./ml penicillin, 100 µg/ml streptomycin and 3 mg/L
[13C315N]-pantothenate.

•

SILEC Ultra-labeling media. Mammalian cells: Prepare pantothenate-free media
containing 3% heat-inactivated csFBS, 2 mM L-glutamine, 100 I.U./ml penicillin,
100 µg/ml streptomycin and 3 mg/L [13C315N1]-pantothenate. Insect cells (S2):
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Prepare Schneider’s media containing 3% heat-inactivated csFBS, 2 mM Lglutamine, 100 I.U./ml penicillin, 100 µg/ml streptomycin and 10 mg/L [13C315N]pantothenate.
•

Customization of media. Prepare HBSS media supplemented with Ca2+, Mg2+, 1
g/L D-glucose, 25mM HEPES and the appropriate modifying compound (fatty
acid, xenobiotic, etc.). For example, to generate labeled propionyl-CoA, add 10
mM propionic acid; for labeled BHB-CoA, add 10 mM BHB; for labeled
menadione-CoA, add 20 µM menadione. All media should be filtered and can be
stored at 4°C for up to 3 months. Warm media to 37°C prior to cell treatment for
mammalian cells and to room temperature for insect cells.

•

CoA extraction reagents.
o Extraction solution: 10% (w/v) TCA in dd H2O. Chill on ice prior to
experiment.
o Elution solution: 25mM ammonium acetate in methanol.
o Resuspension solution: 5% (w/v) SSA in dd H2O.
o Hydrolysis solution: If pure [13C315N1]-CoASH is being generated, prepare
40% (w/v) KOH in dd H2O.

•

LC-MS solvents. Prepare, sonicate and degas HPLC solvents prior to LC-MS
analysis. Use solvents of mass spectrometry grade (Fisher Optima grade solvents
are used for our analysis)
o Solvent A: 5mM ammonium acetate in water
o Solvent B: 95:5 ACN:H2O 5mM ammonium acetate in water
o Solvent C: 80:20:0.1 ACN:H2O:formic acid
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3.4 Procedure
Generating labeled CoA standards
1. Thaw frozen cells directly into SILEC expansion media.
2. For Hepa 1c1c7 (adherent) cells, allow cells to reach confluency (3-4 days), wash
two times with PBS, trypsinize and split 1:5 into SILEC expansion media. For S2
(suspension) cells, when cells have reached approximately 1x107 cells/ml, split
into a new flask containing SILEC expansion media at a concentration of 2x106
cells.
3. Repeat step 2, passaging cells in SILEC expansion media three more times. At
this point, CoA species should be greater than 98% labeled. If cell growth or
morphological characteristics are significantly affected, see troubleshooting guide:
Perturbation of cell growth kinetics by SILEC media.
Pause point: Harvest and freeze down one plate of labeled cells in SILEC expansion
media containing 10% DMSO. These cells can be thawed to seed future SILEC
expansions.
4. After the fourth passage, allow cells to reach confluency or 1x107 cells/mL.
5. Ultra-labeling step: Wash cells with 10 mL PBS and replace with SILEC Ultralabeling media and incubate for 24 h.

Testing of SILEC labeling
Short chain acyl-CoA acid extraction:
6. Harvest one plate of cells by scraping gently into media and spin down at 1000g.
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7. Resuspend cells in 1 mL ice-cold extraction solution (10% TCA)
8. Sonicate cells for 30 sec on ice in a pulsatile manner.
9. Spin sonicated cell lysate at 15000g for 5 min to precipitate protein pellet.

Solid phase extraction (SPE):
10. Using a vacuum manifold, condition Oasis HLB SPE columns with 1 mL of
methanol.
11. Equilibrate with 1 mL water.
12. Load acid extracted lysate (supernatant) to columns.
13. Wash column with 1 mL water.
14. Elute CoA compounds into fresh tube by applying three subsequent applications
of 0.5 mL elution solution.
15. Dry samples under nitrogen.
16. Re-suspend in 50 µL of 5% SSA.

LC-MS analysis: (see Chapter 2 for specific LC-MS parameters)
17. Using the LC-MS specifications in Figure 2, perform a CID neutral loss scan of
507 amu, scanning a parent mass range of m/z 750 to m/z 1200. Sample injections
of 10 µL should be used for analysis.
18. Characterizing CoA SILEC Profile: Generate a m/z list from the neutral loss scan
and compare them against a m/z list of CoA species (Appendix), and prepare a
SRM experiment for each of these parent ions and their respective product ions.
The singly charged protonated molecule should be used for the parent CoA while
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the associated product ion of 507 amu lower than the parent protonated molecule
should be used. For example: acetyl-CoA has a parent protonated molecule of
m/z 810.1 and a product ion at m/z 303.1 while [13C315N1]-acetyl-CoA has a parent
protonated molecule of m/z of 814.1 and a product ion at m/z 307.1
19. Determining labeling efficacy: Re-inject and analyze the sample using the LCSRM/MS method, monitoring both the labeled and unlabeled channels to
determine the amount of unlabeled CoA remains for each acyl-CoA.
20. Confirmation of acyl-CoA species: To confirm the identity of the labeled CoA
species, spike extracted SILEC standards with a mixture of the CoA thioesters of
interest (1 pmol each) and repeat the LC-SRM/MS analysis. The labeled and
unlabeled compounds should co-elute. This is particularly important when
multiple peaks arise or if there are multiple isobaric CoA species with similar
parent and product ions.

Harvesting
21. If there are certain CoA species you are interested in that are not represented in
the mixture, further steps may need to be taken (see “Generating customized
SILEC standards”). In the case of incomplete labeling, systematic
troubleshooting may be necessary (See troubleshooting section: Incomplete
labeling). If one or more CoA thioesters of interest are not represented, continue
on to step 23 to generate “customized” SILEC standards. If labeling is complete
(> 99% labeling) and CoA profile is satisfactory, perform CoA extraction for all
plates (steps 7-10).
51

22. Pool together acid soluble SILEC extracts, label batch and freeze at -80°C in 10
mL aliquots.
Pause point: The pooled acid soluble extracts contain the SILEC standards that will later
be spiked into cell or tissue samples. These standards can be stored indefinitely at -80°C,
but should be spiked into a new standard curve for each analysis. Avoid repetitive
freeze-thaw cycles.

Generating customized SILEC standards
23. (Continued from step 21) Wash half of the plates 2X with PBS.
24. For the washed plates, replace with customization media and incubate washed
plates in treatment media for 1 h.
25. Test labeling using steps 17-20
26. After incubation, harvest and extract CoA from all plates (steps 7-10) and pool
together. This pooled extract should contain a SILEC CoA profile with increased
levels of the species of interest.
CRITICAL STEP: It should be noted that using exogenous biological and toxicological
stimuli to change the CoA profile in a given cell types is largely empirical and needs to
be optimized for different cell systems and conditions. Prior to scaling up, optimization
can be performed in unlabeled cells, though should be confirmed in labeled cells as well.
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Producing purified [13C315N]-CoASH
27. (Continued from step 5) After overnight incubation in ultra-labeling media,
perform steps 6-9 for all plates and pool together acid soluble lysates, which
contain CoASH and short chain acyl-CoAs.
28. Adjust pH of lysate to ~13 with 40% KOH w/v. (Add 500 µL KOH to 5 mL TCA
extract) and incubate at room temperature for 1 h.
29. Adjust pH of lysate to 6 with formic acid.
30. Purify labeled CoA using either preparative HPLC (monitor UV wavelength 254)
or SPE extraction using previously described procedures.
31. Dry down hydrolyzed extract, which contain purified [13C315N]-CoASH. This
product can now be used to chemically synthesize a particular CoA derivative.73,
123-125

Utilizing SILEC standards for CoA analysis
32. Thaw an adequate amount of previously generated acid-extracted SILEC CoA
internal standard mixture. Generally, 1 mL of internal standard mixture is needed
for every 5 samples. After thawing, mix thoroughly by vortex-mixing and leave
on ice.
CRITICAL STEP: It is important to determine the amount of labeled SILEC CoA
standard needed prior to the experiment. If multiple batches are necessary for a
single experiment, these batches must first be pooled together prior to application to
samples/standard curve. Due to the biosynthetic nature of SILEC generation, there
can be significant batch-to-batch variability and likewise, using different batches of
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labeled internal standards in different samples of the same experiment can lead to
erroneous measurements.
33. To prepare standard curve samples: thaw and mix equal concentrations of
unlabeled CoA standards of interest creating a master mix, and perform two-fold
serial dilutions, from 1 µM down to approximately 10 nM, in extraction solution
(10%TCA). Mix 50 µL of each dilution with 0.75 mL extraction solution and 0.2
mL of thawed SILEC CoA internal standard extract (for a final volume of 1 mL)
and vortex. This will generate a standard curve from approximately 100 fmol to
10 pmol of each CoA standard on column.
34. To prepare experimental samples: add 0.8 mL ice cold TCA along with 0.2 mL of
the same SILEC internal standard mixture to harvested cell pellets, snap-frozen or
lyophilized tissues, or purified extracted cells (platelets, lymphocytes, fibroblasts,
etc.)
35. For cell samples, sonicate for 30 sec on ice in a pulsatile manner. For tissue
samples, homogenize according to standard protocols. In either case, perform the
same processing step for the standard curve samples as well.
36. Spin processed acid extracted lysate at 15000g for 5 min to precipitate protein
pellet.
37. Perform SPE extraction of CoA species as previously described (steps 10-16).
38. Re-suspend samples in 50 µL 5% SSA.
PAUSE POINT: Samples and standards can be immediately analyzed or frozen at -80°C
for future analysis. Since the SILEC CoA internal standards are included, effects on
sample stability should be reflected in the internal standards as well.
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39. For analysis, inject 10 µL from each sample or standard mix and perform LCMS/MS analysis using selected reaction monitoring (SRM) mode developed
previously.
40. From the raw data, develop a standard curve for each of the CoA species, with the
x-axis as the known amount of injected standard and the y-axis as the ratio of
unlabeled to labeled integrated peak areas.
41. Use the regression line from this standard curve to calculate the amount of each
CoA thioester in samples.

TIMING
Typical times used in our laboratory for the various steps are as follows:
SILEC labeling:
•

Expansion: 12-16 days

•

Ultra-labeling: 1 day

•

Testing of labeling: 3 h

•

Customization: 1 h to 12 h

•

Testing of labeling: 3 h

•

Harvesting and Extraction: 30 min

Application of internal standards
•

Sample preparation: approximately 1 h

Analysis: 30 min per sample. One day per experiment, total time: 15-20 days.
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3.5 Troubleshooting
3.5.1 Perturbation of cell growth kinetics by SILEC media.
Changes in cell media components may affect a number of cell growth parameters
such as doubling times, cell viability, adherence and morphological characteristics.
While slightly slower cell growth is expected with SILEC media, if there is severely
deranged cell growth or morphological changes, media components should be serially
investigated. Serum. While serum is necessary for many cell lines, the lack of serum
standardization and lot-to-lot variability makes it very challenging to reproducibly scaleup many biosynthetically-generated compounds. Charcoal-stripping is commonly used to
standardize serum and csFBS is the optimal serum for our purposes as it dramatically
reduces unlabeled pantothenate, which can contaminate the labeled CoA pool. In
addition to removing pantothenate, however, charcoal-stripping also removes a number
of other serum components including hormones, growth factors and other B vitamins,
which can also negatively affect cell growth.114, 115 One method to overcome this is by
either increasing the amount of csFBS or using dFBS during the expansion stage, which
may be enough to overcome these effects. Although dFBS would slightly increase the
level of unlabeled pantothenate, it still has considerably less pantothenate than undialyzed
serum. This may improve cell growth during the expansion phase. If it is found,
however, that dFBS is necessary during the ultra-labeling step, the concentration should
be substantially reduced and the concentration of pantothenate should be increased to
lower the percentage of unlabeled pantothenate in the serum. If both csFBS and dFBS
are prohibitive to cell growth, and uFBS is necessary, a different cell line should be
considered as the high level of residual pantothenate in uFBS would be difficult to
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overcome by simply adding more labeled compound. Other media components.
Commercial services are available for the production of specialty media such as
pantothenate-omitted RPMI 1640 media, which is used in our protocol. However, should
you choose to prepare your own SILEC media, make sure all components are dissolved
and that your cells show similar growth characteristics when this media is supplemented
with standard FBS and the same concentration of pantothenate. Since certain media
components can also degrade over time, prepared media should be kept at -20°C for long
term storage. Finally, contamination with mycoplasma can slow cell growth. Therefore,
thaw fresh cells or perform simple tests for mycoplasma to eliminate this possibility.

3.5.2 Incomplete labeling.
As previously mentioned, a critical aspect to biosynthetic generation of labeled
standards is minimizing the unlabeled fraction. Typical SRM chromatograms of CoASH
harvested from [13C315N1]-pantothenate-labeled cells are provided in Figure 3.4. Figure
3.4A shows an example of insufficient labeling, with greater than 5% of the CoASH
unlabeled, while Figure 3.4B depicts CoASH from a SILEC batch with more complete
labeling (less than 1% unlabeled). There are three underlying causes for incomplete
labeling: (1) contaminating unlabeled pantothenate in the media, (2) unlabeled
pantothenate in the [13C315N]-pantothenate stock, and (3) insufficient turnover of
pantothenate or CoA pool within the cell line. First, determine if there is contaminating
unlabeled pantothenate in the media, as this is the most likely cause of the incomplete
labeling. For mammalian cell culture, if the pantothenate-omitted media was
commercially prepared, verify that pantothenate is not in the formulation. If this was
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Figure 3.4 Comparison of complete and incomplete labeling. LC-MS (SRM)
chromatograms of CoASH harvested from [13C315N1]-pantothenate-labeled cells. Both
unlabeled CoASH (m/z 768  261) and [13C315N1]-CoASH (m/z 772  265)
chromatograms are presented to illustrate (A) sub-optimal labeling (>5% unlabeled), and
(B) near-complete labeling (<1% unlabeled). Extraction and analysis were performed as
specified in the protocol.
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prepared in house, verify that the base nutrient mix you are using does not contain any
pantothenate. For insect cell culture, Schneider’s media contains yeast extract, which
contains a variable, though significant level of different B vitamins, including
pantothenate. For this reason, a higher concentration of labeled compound is needed for
insect SILEC preparation.
If there is incomplete labeling in insect cells, it could very well be coming from
increased levels of pantothenate in the yeast extract (yeastolate). To overcome this, the
ultra-labeling step can be performed with HBSS media overnight containing 4 mg/L
labeled pantothenate which should increase labeling to greater than 99%. More likely,
however, the unlabeled pantothenate is originating from the csFBS. While there should
be less than 0.1 mg/L of pantothenate remaining in the csFBS93 (resulting in an effective
0.01mg/L in media containing 10% serum), it is possible that a particular lot of serum
may have more, or that a higher concentration of serum is needed for a particular cell line.
Adding additional labeled pantothenate to the media should overcome this problem. If
this is a newly occurring problem, check the lot of the csFBS, as lot-to lot variability can
exist for serum. If a particular lot of csFBS has worked in the past, it may be worth
ordering several bottles of this for future use. The serum can be frozen down and stored
at -20°C for long-term storage. The second possibility is that the stock itself is
contaminated with unlabeled pantothenate. This can be assessed by performing mass
spectral analysis of the labeled stock. To do this, reconstitute a small amount of the
labeled pantothenate stock and using flow infused syringe injection and SRM analysis.
The relative ratio of labeled to unlabeled pantothenate represents the maximal purity that
the CoA can be labeled. If this is not acceptable, another source of labeled pantothenate
59

should be sought. For our experiments, we found that the isotopic purity of the stock was
greater than 99.5%. Finally, the last problem that can arise, particularly with suspension
culture is that a certain amount of the unlabeled compound is not turning over and
remains in the cellular pool due to cell death or senescence. This is more of a problem
with SILAC protocols because different proteins turn over at various frequencies and
salvage pathways of particular amino acids may cause these unlabeled species to continue
to propagate in culture. For CoA species, this turnover is greater and more than 50% of
the CoA can turnover in the cell in 24 h,93 although different CoA species may not
turnover as rapidly. To overcome this problem, simply passage the cells two or three
more times in the expansion media. If the cells are being split 1:3, less than 0.5% of the
original cell mass will remain after 5 passages. While this may add an additional week to
the expansion phase, this would replace at least 99.5% of the original cell mass and
likewise the original unlabeled CoA. Finally, batch-to-batch variability can arise from
the biological variability of cells in different stages of the cell cycle. This effect can be
overcome by synchronizing cells with serum-free media prior to the final step of labeling.

3.5.3 Problems in sample preparation and LC-MS
SPE. Oasis HLB columns (Waters) have been found to be optimal for short-chain
acyl-CoA extraction, though other methods such as liquid-liquid extraction could be used
as well.67, 93 However, when the experiment involves more complex biological matrix
such as in tissue samples, or if a larger amount of biological material is being used (to
measure lower abundance analytes), a greater matrix effect may be observed. In our own
experience, we have extracted CoA species from liver, brain and adipose tissues. Brain
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and liver tissue contain abundant acyl-CoA metabolites, while adipose tissue was found
to contain significantly less CoA content, likely due to the decreased cellular content per
unit weight of tissue. Also, after homogenization and centrifugation of the adipose tissue,
a significant layer of fatty tissue remained on the top of the acid extract. Therefore, the
aqueous layer was transferred to a fresh tube, avoiding the lipid layer, and centrifuged
again prior to SPE extraction. In each case, repeating the SPE washing step (with water)
one or two times may help. Also, using a molecular weight cut off filter prior to SPE
extraction may also reduce the matrix effect, though this will increase processing time.
Using methanol containing concentrated ammonia may improve elution for all
extractions.67
LC. While acyl-CoA analysis is generally robust, repeated injections of cell and
tissue extracts can lead to build-up of biological materials on the column, which can lead
to distortions in peak shape.69 For this reason, we have added solvent C as a column wash
step. If peak distortion is occurring, increasing the wash step as well as slowing down the
ramp time for washing can improve column performance, though this will also increase
run times. Also lowering the pH of this wash can also improve the ruggedness of the
method.
MS. In the case of inadequate sensitivity, use acetonitrile instead of methanol in
the mobile phase whenever possible, and decrease formic acid concentration during MS
analysis. Also, if LC-SRM/MS analysis is increased to include a large number of species,
a proper number of analytical points may not be achieved across each peak and may lead
to incorrect quantitation, even with internal standards. To overcome this, SRM dwell
time should be reduced so as to increase the number of points across the peak. For
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example, if measuring eight CoA species along with their internal standards (16 analytes
total), using dwell times of 80-100 milliseconds may be acceptable. However, if the
number of analyzed CoA are increased to 20-30 species (40-60 total), shorter dwell times
(20-30 ms) may be necessary to achieve enough points across the peak. Also, dividing
up the analysis into shorter segments can allow for longer dwell times.
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Chapter 4: Development of LC-MS method to monitor CoASSG and its relevance
to mitochondrial oxidative stress
4.1 Abstract
Despite technical developments in measuring reactive species in the mitochondria,
few markers of mitochondrial oxidative stress are currently available. It has been
previously reported that the ratio of CoASH to CoASSG can be used as a marker of
intramitochondrial oxidative stress. However, currently analytical methods lack
adequate sensitivity for rigorous measurements of CoASSG in cell culture. In this
chapter, we present a novel LC-SRM/MS method to measure CoASSG. To accomplish
this, CoASSG was first synthesized from CoASH and GSSG. SILEC methodology was
used to generate isotopically labeled [13C315N1]-CoASSG to be used as an internal
standard for measuring this compound from cell culture. Menadione and rotenone, both
known to generate mitochondrial ROS, were applied to murine heptatoma cells (Hepa
1c1c7) and intracellular levels of CoASH, CoASSG and various short chain acyl-CoA
thioesters were quantified using this method. Menadione was found to significantly
increase CoASSG and decrease CoASH, the latter likely resulting from arylation of
menadione and sequestration of the CoASH pool. Although rotenone had a minimal
effect on CoASSG levels, it had a dramatic impact on other CoA thioesters levels at
much lower doses, a finding which is further explored in the following chapter. This
methodology allowed more rigorous and sensitive measurement of CoASSG and will
allow further exploration into its mechanism of formation, as well as aid in finding
biomarkers for mitochondrial oxidative stress.
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4.2 Introduction
Oxidative stress represents a pathological state in which cellular antioxidant
defenses are overwhelmed by oxidative processes arising from endogenous or exogenous
sources.126 During oxidative stress, several highly labile ROS can damage intracellular
macromolecules proteins, lipids, and DNA (both nuclear and mitochondrial).127-130
Accumulation of this damage is believed to contribute to cancer, neurodegenerative
diseases and is considered to be a central factor in aging.131-134

The mitochondria are a

major source and target for ROS. Although numerous reports have suggested
mitochondrial dysfunction causes increased mitochondrial ROS generation through
reverse electron transport,135-138 an increase in mitochondrial ROS does not necessarily
equate to mitochondrial oxidative stress. In fact, under normal conditions of
mitochondrial respiration, it has been estimated that as much as 0.1 % and 0.5 % of
oxygen consumed the mitochondria is converted to superoxide.139, 140 In addition, ROS
play important physiologic roles in cell signaling.141, 142 Therefore, despite technical
developments in the measurement of reactive species in the mitochondria,143 increases in
ROS or RNS are not necessarily indicative of a pathological state of mitochondrial
oxidative stress, for which few markers are currently available.
Glutathione (GSH) is a highly abundant intracellular thiol that serves not only a
major reducing agent, but also as an essential detoxifier of xenobiotics and potential
damaging electrophiles.106 Glutathione peroxidase can detoxify intracellular H2O2,
generating oxidized glutathione (GSSG), which can be reduced back to GSH by the
action of glutathione reductase. The redox potential of the cell can be assessed by
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measuring the ratio of GSSG: GSH, which is increased during oxidative stress. This can
result from GSH-dependent ROS detoxification pathways being compromised or
overwhelmed.107 CoASH is an abundant mitochondrial thiol and like GSH, which can be
oxidized to GSSG, CoASH can be oxidized to form CoA-CoA disulfide, 65 or can be
converted to CoASSG.73 Although the exact role of this mixed disulfide is unknown,
there is evidence that it has potent vasoconstrictive effects. 46, 50, 51 Like GSSG: GSH, the
ratio of CoASSG: CoASH has been shown to increase during states of intramitochondrial
oxidative stress, such as in rat models of seizures and hyperoxia,53, 55 or in response to
certain pharmacological agents.42 However, the primary method to measure CoASSG has
been with LC-UV, which requires relatively high concentrations of CoASSG and is
inadequate for most practical cell culture applications. In this chapter, we develop a
novel LC-SRM/MS method to monitor CoASSG, along with CoASH and other CoA
thioesters. This assay was then used to assess mitochondrial oxidative stress generated
by menadione, a vitamin K precursor, and rotenone, a classic mitochondrial complex I
inhibitor, both known to generate reactive oxygen species in the mitochondria.135, 144

4.3 Materials and Methods
4.3.1. Materials
Oxidized glutathione (GSSG), menadione and rotenone and were all purchased
from Sigma-Aldrich (St. Louis, MO). Remaining materials were obtained as previously
reported.

4.3.2 Synthesis and purification of CoASSG
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CoASSG was synthesized using a method developed by Chang and Wilken.73
Briefly, a 3 mL solution containing 1 mM CoASH and 10 mM GSSG was prepared in a
50 mM sodium phosphate buffer (pH 6.8). Oxygen was bubbled through the mixture at
37°C for 3 h. CoASSG was purified using preparative HPLC using a reversed-phase
gradient separation Waters Xbridge C18 column (10 x 250 mm, 5 micron) on a Hitachi
HPLC system equipped with a L-7100 pump, L-7400 UV detector (monitoring 254 nm)
and D-2500 Chromato-Integtrator. Solvent A was 5mM ammonium acetate in water was
and solvent B was 5 mM ammonium acetate in methanol. Gradient conditions (%B)
were as follows: 4% for 3 minutes, increased to 50% over 17 minutes, to 80% over 2
minutes, held at 80% for 3 minutes, returned to 4% over 1 min, and re-equilibrated at 4%
for 6 minutes. Flow rate was 3 mL/min. Eluting peaks were collected manually and
identities of both CoASSG and CoASH were confirmed by LC-tandem MS (MS/MS)
analysis on an API 4000 triple quadrupole mass spectrometer (Applied Biosystems).

4.3.2. LC-MS
SILEC standards were prepared as previously described in chapters 2 and 3. LCMS analysis was also performed as previously described. SRM transitions were
determined for CoASSG (m/z 1073.1  566.1) and isotopically labeled [13C315N1]CoASSG was (m/z 1077.1  570.1). Both transitions were added to the previously
described SRM transitions developed for short chain acyl-CoA analysis. Additionally,
we monitored BHB-CoA (m/z 854.1  347.1) and [13C315N1]- BHB-CoA (m/z 858.1 
351.1). A typical LC-MS chromatogram demonstrating baseline separation of BHB-CoA
and malonyl-CoA (isobaric) is provided in the appendix (Figure A.2).
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4.3.3 Cell culture and treatments
Murine hepatoma cells (Hepa 1c1c7) were maintained in RPMI media
supplemented with 10% FBS, glutamine, penicillin and streptomycin at 37°C, with 5%
CO2. Menadione and rotenone stocks were made fresh in DMSO (1 mM). When cells
had reached 80% confluence, they were washed twice with PBS and the media was
replaced with HBSS, containing Ca2+, Mg2+, 10 g/L glucose, 25 mM HEPES and either
menadione (2 µM and 20 µM), rotenone (2 µM and 20 µM), or DMSO (vehicle). After 1
h, cells were harvested by scraping, processed and analyzed as previously described, with
the additional SRM transitions noted above.

4.4 Results
4.4.1 Synthesis and purification of CoASSG
CoASSG was synthesized using modifications to a previously developed
method.73 The disulfide exchange between CoASH and GSSG resulted in the nonenzymatic formation of CoASSG. This was then purified by preparative HPLC-UV,
monitoring absorption at 254 nm. Preparative LC-UV chromatograms of GSSG alone,
CoASH as well as the reaction mixture are provided in figure 4.1. Four distinct peaks
can be observed at 4.00 min (unreacted GSSG), 10.70 min, 11.56 min (unreacted
CoASH), and 12.44 min. The remaining two peaks (10.70 min and 12.44 min) were
collected and concentrated with nitrogen, and a small aliquot was re-injected to confirm
purity. CID MS/MS revealed that peak 2 (10.70 min) was in fact CoASSG, and the
product ion spectra for this molecule along with the product ion spectra for CoASH are
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(A)

(B)

GSSG

(C)

CoAS H

CoASSG

Figure 4.1 Synthesis and purification of CoASSG. CoASSG was synthesized by using
thiol exchange reaction of CoASH with GSSG. The reaction mixture was separated and
collected using preparative HPLC, monitoring UV absorption at 254 nm. LC-UV
chromatograms showing (A) GSSG alone, (B) CoASH alone and (C) reaction mixture of
CoASH and GSSG. Peaks were collected, concentrated and identified using CID-MS
(Figure 4.2).
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provided (Figure 4.2). Like all acyl-CoA thioesters, both CoASH and the mixed disulfide
CoASSG were shown to have their most prominent fragment ion to have a neutral loss of
507 amu. For CoASH, the optimal transition was 768.1  261.1 (as has been previously
shown) while for CoASSG, the optimal transition was 1073.1  566.1. The spectra
found for CoASSG is consistent with a fast atom bombardment spectra previously
published.42 These transitions were added to the previously developed SILEC method.
Figure 4.3 shows a LC-SRM/MS chromatogram of acid extracted CoA species from a
mixture of SILEC-labeled and unlabeled Hepa 1c1c7 cells.

4.4.2 Menadione affects CoASSG: CoASH ratio more than rotenone
Hepa 1c1c7 cells were treated with increasing doses of menadione or rotenone for
1 h, and short-chain acyl-CoA species, along with CoASH and CoASSG were analyzed
using the described methodology (figure 4.4) Rotenone did not significantly increase
levels of CoASSG as we had originally suspected, even at 20 µM. Menadione treatment,
on the other hand, resulted in significant decreases in CoASH and increases in CoASSG.
We had previously performed an experiment from chapter 3 in which we generated
labeled [13C315N1]-menadione-CoA with treatment of SILEC labeled cells with
menadione. We have presented the LC-constant neutral loss/MS spectrum from that
study in figure 4.5, which illustrates the increase in [13C315N1]-menadione CoA as well as
a decrease in [13C315N1]- CoASH with menadione treatment. In addition, changes in
short chain acyl-CoA species were also monitored and are presented in figure 4.6.
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Figure 4.2 Collision-induced dissociation (CID) mass spectra for CoASH and CoASSG.
Preparative HPLC effluent corresponding to UV peaks (254 nm) were collected,
concentrated and subjected to CID. CID-mass spectra as well as fragmentation schemes
for (A) CoASH (MH+, m/z 768), and (B) CoASSG (MH+, m/z 1073).
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Figure 4.3 LC-SRM/MS chromatograms of CoASH and CoASSG, along with SILEClabeled stable isotope analogs.
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Figure 4.4 Dose-dependent effects of menadione and rotenone on CoASH, CoASSG and
CoASSG: CoASH ratio. Hepa 1c1c7 cells treated with rotenone and menadione (2 µM
or 20 µM) or DMSO (vehicle) and processed for intracellular levels of (A) CoASH (B)
CoASSG (C) and CoASSG: CoASH. Error bars are SEMs for n=4, * p< 0.005
compared with DMSO.
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(A)

(B)

(C)

Figure 4.5 LC-constant neutral loss/MS with a neutral loss of m/z 507 of SILEC labeled
hepatocytes treated with (A) DMSO (vehicle), (B) 10 µM menadione, or (C) 20 µM
menadione for 1 h. The parent ions (MH+) of the observed CoA species are [13C315N1]CoASH (MH+, m/z 772), [13C315N1]-acetyl-CoA (MH+, m/z 814), [13C315N1]-succinylCoA (MH+, m/z 872), [13C315N1]-HMG-CoA (MH+, m/z 916), and [13C315N1]-menadioneCoA (MH+, m/z 942).
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Figure 4.6 Dose-dependent effects of menadione and rotenone on selected short-chain
acyl-CoA thioesters. Hepa 1c1c7 cells treated with rotenone and menadione (2 µM or 20
µM) or DMSO (vehicle) and processed for intracellular levels of (A) acetyl-CoA (B)
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* p< 0.005 compared with DMSO.
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4.5 Discussion
In this chapter, we have developed for the first time an LC-SRM/MS method to
measure CoASSG. Using the previously described SILEC methodology, we are also able
to generate isotopically labeled [13C315N1]-CoASSG, which can be used as an internal
standard for measuring this compound from cell culture. This methodology allows more
rigorous as well as sensitive analysis of CoASSG in cell culture, where lower
concentrations of CoA species limits the application of currently available analytical
methods. As CoASSG: CoASH ratio is a purported measure of intramitochondrial
oxidative stress, we treated cells with agents known to cause oxidative stress in the
mitochondria. Our assay has revealed that menadione, but not rotenone, causes a
significant increase in CoASSG, particularly at higher doses.
In addition to increasing intracellular levels of CoASSG, menadione caused
decreases in CoASH levels, likely due to arylation of CoASH, as thiols are known to
react readily with redox cycling quinones.145 Additionally, in chapter 3 we demonstrated
the generation of [13C315N1]-menadione-CoA internal standards by treating SILEC
labeled cells with menadione. In figure 4.5, we presented the LC-constant neutral
loss/MS spectrum from that study, which illustrates the increase in [13C315N1]-menadione
CoA as well as a decrease in [13C315N1]- CoASH with menadione treatment. Though this
was a qualitative rather than a quantitative assessment, a substantially larger m/z 942
peak (corresponding to [13C315N1]-menadione CoA) is seen with 20 µM compared to 10
µM menadione treatment, as well as a much more substantial decrease in [13C315N1]CoASH. A more thorough quantitative dosing analysis to assess the effects of menadione
treatment on both menadione-CoA levels and decreases in CoASH levels is needed. This
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increase in CoASSG could be a result of the detoxification of menadione, from increased
mitochondrial oxidative stress, or a combination of both processes. Although rotenone
did not appear to increase CoASSG levels significantly, it did, however, decrease
intracellular levels of CoASH, succinyl-CoA and propionyl-CoA and increased BHBCoA levels even at 2 µM. Further exploration of these changes in human cell lines are
described in the following chapter.
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Chapter 5: Rotenone-mediated changes in intracellular CoA thioester levels:
implications in mitochondrial dysfunction
5.1 Abstract
Rotenone is a natural organic pesticide and potent complex I inhibitor shown to
cause Parkinson-like neurodegeneration in rodents and has recently been linked to PD in
humans. In this chapter, rotenone-mediated effects on intracellular levels of various CoA
thioesters were monitored using a stable isotope dilution LC-MS methodology. LCSRM/MS analysis with SILEC standards were performed to rigorously quantify dosedependent effects of rotenone on intracellular short chain acyl-CoA species in various
human cell lines, including neuroblastoma (SH-SY5Y), hepatoma (HepG2) and
bronchioalveolar carcinoma (H358) cells. To further characterize the temporal nature of
these changes in a neuronal cell type, a time course study was performed in SH-SY5Y
cells. Finally, stable isotopic tracer analysis using [U-13C6]-glucose was performed in
these cells in the presence or absence of rotenone. Rotenone induced a dose-dependent
decrease in succinyl-CoA and increase in BHB-CoA in all three cell lines. Isotopic tracer
analysis revealed that rotenone inhibited [U-13C6]-glucose-derived acetyl-CoA and
succinyl-CoA biosynthesis in SH-SY5Y neuroblastoma cells. These changes may reflect
compensatory metabolic changes in response to rotenone.

Portions of this chapter have been previously published (Basu SS, Blair, IA. Chem Res Toxicol, 2011).
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5.2 Introduction
Numerous studies have suggested a link between pesticide exposure and PD, 146
particularly to rotenone and paraquat, two naturally occurring organic pesticides. A
recently published nested case-control study demonstrated a 2.5 fold increase in the
relative risk of developing PD amongst farmers exposed to either rotenone or paraquat.147
Although both pesticides are mitochondrial toxins, they appear to have distinct
toxicological mechanisms.25, 148-150 The focus of this chapter is to explore the effect of
rotenone on central metabolic pathways in the cell.151, 152 The highly lipophilic nature of
rotenone allows it to enter the blood brain barrier, freely cross cellular membranes and
accumulate in subcellular organelles such as the mitochondria. Once in the mitochondria,
rotenone is known to bind to complex I (NADH-ubiquinone oxidoreductase), the first
enzyme complex of the mitochondrial respiratory electron-transport chain. Binding of
rotenone to complex I prevents the transfer of electrons from iron sulfur clusters to
ubiquinone,135, 153 affecting oxidative phosphorylation and generating potentially
damaging ROS.138, 140, 154 Chronic, low dose administration of rotenone in rats has been
shown to result in selective nigrostriatal degeneration and formation of α-synucleinpositive cytoplasmic inclusions (similar to Lewy bodies) in nigral dopaminergic neurons,
resulting in neurodegenerative features similar to those seen in PD.26, 155, 156 Although the
majority of research has focused on rotenone-mediated complex I inhibition and ROS
formation, rotenone has been shown to have effects independent of complex I
inhibition,157 and also induces significant metabolic alterations both in vitro and in vivo.
Technological developments in both MS and nuclear magnetic resonance (NMR) have
produced a growing number of metabolomic assays to assess changes in intracellular and
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extracellular metabolites.158, 159 Using these methodologies, in vitro treatment with
rotenone was found to induce significant and unique changes in a number of cellular
metabolites, including various Krebs cycle organic acid intermediates as well as
intermediates and end-products of other major bioenergetic pathways.160, 161
In this study, we further explored metabolic changes induced by rotenone by
analyzing its effects on intracellular levels on various short chain acyl-CoA thioesters,
which are known to be involved in a number of metabolic pathways.100 To accomplish
this, we used stable isotope dilution LC-MS methodology, which allows more rigorous
quantification for biomarkers and endogenous metabolites,91, 93 using the methodology
described in Chapters 2 and 3. We analyzed the dose-dependent effects of rotenone on
intracellular levels of short chain acyl-CoA species in various human cell lines, including
neuroblastoma (SH-SY5Y), hepatoma (HepG2) and bronchioalveolar carcinoma (H358)
cells. To further characterize the temporal nature of these changes in a neuronal cell type,
a time course study was performed in SH-SY5Y cells. Finally, stable isotopic tracer
analysis using [U-13C6]-glucose, [1,2-13C2]-acetate, and [13C315N1]-pantothenate was
performed in these cells in the presence or absence of rotenone. By monitoring the
isotopomer distribution pattern in the measured CoA species, the fate of the labeled
atoms and consequently their flux through different metabolic pathways was assessed.
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5.3 Materials and Methods
5.3.1 Materials
[1,2-13C2]-acetate was purchased from Cambridge Isotopes (Andover, MA). All
other materials used in this chapter were obtained as previously reported.

5.3.2 Generation of stable isotope labeled CoA internal standards
Stable isotope CoA and CoA thioester internal standards were generated as
described in chapters 2 and 3, with minor modifications as follows. After 30 plates of
Hepa 1c1c7 cells were ultra-labeled (overnight incubation in with 3% csFBS and 3 mg/L
[13C315N1]-pantothenate), 10 plates were treated with 10 mM propionate, 10 plates were
treated with 10 mM BHB, and 10 plates were left untreated for 1 h. Cells were then
harvested and SILEC CoA species were harvested and extracted as described. TCA
extracts from all three groups were pooled, aliquoted, frozen, and stored at -80°C.

5.3.3 Cell culture and rotenone treatments
HepG2 and H358 were maintained in RPMI 1640 media and SH-SY5Y cells were
maintained in 1:1 F12:DMEM, each media supplemented with 10% FBS, 2 mM Lglutamine, penicillin and streptomycin. Cells were incubated at 37 °C and 95% humidity
with 5% CO2. Rotenone solutions in DMSO were freshly prepared prior to treatment.
Serial dilutions of rotenone were made for dosing and time course studies and treatments
were performed when cells were approximately 80% confluent and added directly to the
plate (DMSO < 1% volume). Control cells were treated with an equal amount of DMSO
containing no rotenone. For dosing study, cells were treated for 1 h prior to harvesting.
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For time course study, SH-SY5Y cells were treated in the same manner, and harvested at
1, 2, 4, and 6 h after treatment.

5.3.4 Extraction and measurement of CoA using SILEC standards
Analyses of CoASH and CoA thioesters were performed using modifications of
methodology previously described. Briefly, after treatment, cells were harvested by
scraping, centrifuged at 500g, and resuspended in 1 mL ice-cold 10% TCA containing
biosynthetically generated stable coenzyme A thioesters (SILEC). Cells were then pulsesonicated on ice followed by centrifugation to remove protein debris. The supernatant
containing the short chain acyl-CoA species were purified by solid-phase extraction using
Oasis HLB SPE columns. The eluent was dried down under nitrogen and resuspended in
50 µL 5% SSA. CoA standards were processed in a similar fashion. To determine
approximate cell count, a parallel plate of cells split on the same day were counted.
Stable isotope dilution LC-MS analysis was performed as previously described.

5.3.5 Isotopic tracer analysis
SH-SY5Y cells were maintained in culture as described above. For isotopic
tracer analysis, glucose-free DMEM media was prepared containing 10% csFBS,
penicillin, streptomycin, glutamine and supplemented with 1 mg/L of either unlabeled
glucose or [U-13C6]-glucose. Cells were washed with PBS and treated for 6 h with
labeled media containing 100 nM rotenone or DMSO (control). After treatment, CoA
species were extracted as previously described except without SILEC standards. LC-MS
methods conducted in the same manner except that in addition to the M0 CoA molecule,
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the M1, M2, M3 and M4 isotopomer of each metabolite was also quantified. Label-free
cells were used to generate an isotopomer enrichment matrix for acetyl-CoA, succinylCoA, BHB-CoA and CoASH. An isotopomer array generated for each sample was
multiplied by the inverse of the matrix generated from the label free cells to determine
the absolute concentration of each isotopomer and presented as a percentage of the total
isotopomers for each CoA derivative as described by Fernandez et al.162 A similar
methodology was used to monitor labeling in Krebs cycle organic acids, which were
extracted and derivatized with N-tert-Butyldimethylsilyl-N-methyltrifluoroacetamide
(MTBSTFA), according to a previously published protocol.163 An LC-SRM/MS method
was developed to measure derivatized citrate, aKG, succinate and malate along with their
M0 to M4 isotopomers. For acetate labeling, SH-SY5Y cells were treated in the same
media except that instead of 1 mg/mL [U-13C6]-glucose, 10 mM [1,2-13C2]-acetate was
used, and cells were incubated in this media for 6 h. For pantothenate isotopic tracer
analysis, SILEC media supplemented with 10% csFBS and 3 mg/L [13C315N1]pantothenate was used and cells were incubated for 3 or 15 h. In both cases, untreated
cells were used for the background isotopomer distribution matrix determination.

5.4 Results
5.4.1 Rotenone dosing study
Rotenone was found to induce a dose-dependent change in the short chain acylCoA profile SH-SY5Y, HepG2 and H358 cells. Most notably, there was a significant
decrease in levels of succinyl-CoA (Figure 5.1A) and a concomitant increase in
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Figure 5.1 Rotenone-mediated changes in intracellular CoA thioester levels. (A)
Succinyl-CoA, and (B) BHB-CoA, extracted from SH-SY5Y cells, HepG2 cells, and
H358 cells treated with rotenone for 1 h, in triplicate. Values are shown as % of the
maximal level for each cell line. (C) Time course of rotenone-mediated changes in
intracellular succinyl-CoA and BHB-CoA. SH-SY5Y cells were treated with 100 nM
rotenone, harvested at time points up to 6 h, and processed for CoAs. Error bars show
SEMs for triplicate determinations. Absolute levels for all measured CoA species are
provided in the appendix (Table A.4).
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BHB-CoA (Figure 5.1B) after 1 h of treatment with an IC50 of < 100 nM in all cell types.
There were also significant changes in a number of other acyl-CoA thioesters, which
varied among different cell types (appendix, Table A.4). To characterize the temporal
nature of these changes, SH-SY5Y cells were treated with 100 nM rotenone and
harvested at time points up to 6 h and analyzed for CoA thioesters. The observed
changes seen in succinyl-CoA and BHB-CoA persisted for at least 6 h (Figure 5.1C).
Overall, these results show that rotenone induces a rapid and persistent metabolic
rearrangement in a variety of cell types, similar to changes observed during fasting.20

5.4.2 Isotopic tracer analysis
Although the observed changes indicate that rotenone induces a significant
metabolic disturbance, absolute CoA measurements represent only a “snapshot” of this
metabolic state. To gain additional information on the cumulative flux through different
pathways, cells were incubated with [U-13C6]-glucose and isotopomer distribution of the
resulting CoA derivatives was analyzed. [U-13C6]-glucose (M6) taken up by cells is
converted during glycolysis into two [13C3]-pyruvates (M3), which can subsequently be
converted by pyruvate dehydrogenase into [13C2]-acetyl-CoA (M2). Both labeled
carbons from acetyl-CoA are then incorporated into citrate and eventually form [13C2]succinyl-CoA (M2) in the first turn of the Krebs cycle. Additional cycles can result in
the M3 and M4 succinyl-CoA isotopomers. It should be noted that isotopic tracer
analysis is complex, with numerous intersecting metabolic pathways. For our purposes,
however, this simplified interpretation made it possible to asses major changes that were
occurring in the cells. SH-SY5Y cells were washed and treated with glucose-free media
84

supplemented with either unlabeled glucose or [U-13C6]-glucose with or without 100 nM
rotenone. The unlabeled cells were used to determine isotopic contributions of unlabeled
CoA species to each isotopomer, which were subtracted from the labeled CoA species
using a matrix analysis.162
Rotenone significantly decreased the incorporation of glucose-derived carbon
atoms into acetyl-CoA, from 23% to 5% demonstrating that rotenone inhibited the
glucose-derived biosynthesis of acetyl-CoA (Figure 5.2A). Interestingly, while there was
a decrease in the % labeled acetyl-CoA, the overall concentration of acetyl-CoA did not
change significantly (appendix, Table A.4) Rotenone also significantly decreased the M2,
M3 and M4 isotopomers of succinyl-CoA, indicating decreased conversion of glucose to
succinyl-CoA. Therefore, the decrease in absolute succinyl-CoA concentration was due,
in part, to decreased glucose-derived flux through the Krebs cycle (Figure 5.2A). Lastly,
there was no isotopic labeling of CoASH, confirming that the labeling occurred only in
the acyl moiety. The decreased flux of glucose-derived carbons was also observed in the
Krebs cycle organic acids (Figure 5.2B), confirming the decrease in glucose-derived
carbons in the Krebs cycle. There was also a total relative decrease of labeled carbons
through the cycle both groups, consistent with the relative number of steps from acetylCoA entry into the cycle. Also, rotenone induced increased incorporation of [1,2-13C2]acetate into acetyl-CoA (Figure 5.3A) and decreased incorporation of labeled [13C315N1]pantothenate into CoASH and all of the measured acyl-CoA species at both 3 h and 15 h
(Figure 5.3B).
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Figure 5.2 Rotenone mediated effects on isotopic labeling of [U-13C6]-glucose. (A)
Effect of rotenone on the biosynthesis of glucose-derived acetyl-CoA and succinyl-CoA.
SH-SY5Y cells were incubated in media containing [U-13C6]-glucose and 100 nM
rotenone or DMSO (vehicle) for 6 h. Isotopomer distributions are shown in relation to
the Krebs cycle. Error bars are SEMs for n=5, * p< 0.005 compared with DMSO vehicle.
(B) Effect of rotenone on the biosynthesis of glucose-derived citrate, aKG, succinate, and
malate. SH-SY5Y cells were incubated in media containing [U-13C6]-glucose and 100
nM rotenone or DMSO (vehicle) for 6 h. Error bars are SEMs for n=4, * p< 0.005
compared with DMSO.
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Figure 5.3 Rotenone mediated effects on isotopic labeling of [U-13C2]-acetate and [U13 15
C3 N1]-pantothenate. (A) SH-SY5Y cells were incubated in media containing 10 mM
[1,2-13C2]-acetate and 100 nM rotenone or DMSO (vehicle) for 6 h. Error bars are SEMs
for n=4, * = p< 0.005 compared with DMSO vehicle. (B) SH-SY5Y cells were
incubated in media containing 3 mg/L [U-13C315N1]-pantothenate and 100 nM rotenone or
DMSO (vehicle) for 3 h or 15 h. Error bars are SEMs for n=3.
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5.5 Discussion
In this chapter, we have shown for the first time that rotenone not only inhibits
glucose-derived formation of both acetyl-CoA and succinyl-CoA, it also induces an
increase in the formation of BHB-CoA in a number of human cell lines. The decrease in
acetyl-CoA labeling would in fact be predicted from the decreased pyruvate
dehydrogenase activity that occurs when there is a high NADH/NAD+ ratio,164 and is
consistent with a recent finding that rotenone causes increased shunting of glycolytic
intermediates into lactate.160 The absence of a decrease in the absolute concentration of
acetyl-CoA indicates either an alternate source of acetyl-CoA or an inhibition of acetylCoA utilization. The increased labeled acetate incorporation into acetyl-CoA (Figure
5.3A) may also be an attempt by the rotenone treated cells to compensate for the
decreased glucose derived acetyl-CoA.
The decrease in succinyl-CoA levels is consistent with a recent study in
Arabidopsis cells, in which a rapid 50% decrease in aKG, the precursor of succinyl-CoA,
was observed after 1 h of rotenone treatment.161 This may be, in part, due an inhibition of
aconitase, which is known to be inhibited by rotenone and ROS formation.165, 166 The
dramatic decrease in intracellular succinyl-CoA (Figure 5.1A) would cause decreased
protein succinylation, a post-translational modification with important regulatory
implications. For example, 3-hydroxy-3-methyl-glutaryl (HMG)-CoA synthase, the ratedetermining enzyme in ketogenesis is inactivated by succinylation, which is, in turn,
regulated by succinyl-CoA concentrations.38 In addition, a recent study has shown that
succinylation of lysine residues occurs as a post-translational regulatory modification to
certain enzymes such as isocitrate dehydrogenase (Figure 5.2).167 In addition to
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decreased succinyl-CoA biosynthesis, increased conversion of succinyl-CoA to succinate
may also contribute to decreased succinyl-CoA levels. The increased succinate could
then be used as a complex II substrate. Since complex I and II both ultimately reduce
ubiquinone, the increased conversion of succinyl-CoA to succinate may allow for
increased complex II activity to compensate for complex I inhibition.
The rotenone-mediated increase in BHB-CoA (Figure 5.1B), an intermediate in
fatty acid β-oxidation,168 together with the minimal incorporation of [U-13C6]-glucose
into BHB-CoA (< 5 %) is indicative of a compensatory metabolic rearrangement to
maintain cellular bioenergetics, allowing the cell to bypass the inhibition of glucosederived acetyl-CoA. This would arise through the intermediate 3-hydroxyacyl-CoA
dehydrogenase-mediated formation of acetoacetyl-CoA169 followed by thiolase
(ACAT1)-mediated formation of acetyl-CoA.170
Finally, the decreased incorporation of pantothenate into CoA (Figure 5.3B) was
also quite striking and somewhat surprising, as we expected an increase in CoA
utilization and turnover during a state of metabolic stress. This does raise the intriguing
possibility that rotenone has effects on the CoA biosynthesis pathway, though this has not
been previously documented. Whether any or all of these changes are a pathological
result of rotenone toxicity, physiological adaptation to diminished OXPHOS function, or
a complex I-independent effect altogether remains to be determined. However, the
prolonged reliance on compensatory pathways could play an important role in rotenone
toxicity in vivo due to differences in the abilities of different tissues or cell types to upregulate or maintain these metabolic rearrangements.
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5.6 Conclusions
In summary, we have shown that SILEC-based stable isotope dilution LC-MS
methodology coupled with isotopomer analysis of CoA thioesters can be used in vitro to
gain insight into the mechanisms involved in the toxicity of environmental agents such as
rotenone. Although rotenone does not completely mimic all aspects of PD,149 it provides
an example of an environmental chemical, which causes a systemic defect in
mitochondrial function that leads to selective nigrostriatal neurodegeneration.171 Stable
isotope LC-MS approaches along with mass isotopomer experiments make it possible to
better characterize the metabolic pathways perturbed by rotenone treatment.
Understanding the changes that rotenone induces in disparate cell types will increase our
understanding of why rotenone affects certain cell types such as dopaminergic neurons,
while sparing other neurons and tissues. These biomarkers might relate specifically to PD
but could also be potentially useful for monitoring other neurodegenerative diseases
involving mitochondrial dysfunction. By understanding the pathways involved, we will
be able to use evidence based prediction of particular pathways to further identify
potential pathways for biomarker discovery in other metabolic and neurodegenerative
diseases.23, 131, 134, 172, 173
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Chapter 6: CoA biomarkers in platelets: application in Friedreich’s Ataxia
6.1 Abstract
Friedreich’s ataxia (FA), the most prevalent inherited form of ataxia, is an
autosomal recessive mitochondrial disease, resulting from a tri-nucleotide expansion
(GAA) in the gene for frataxin, a protein involved in iron sulfur cluster (ISC) formation.
The lack of good FA biomarkers hampers the ability to develop and analyze effective
treatments for this disease. There is growing evidence that metabolic dysfunction plays a
role in the FA pathogenesis. In this study, changes in acyl-CoA species were
characterized using SILEC methodology in a frataxin siRNA knockdown model in
HEK293 cells. In addition, the SILEC method was adapted to measure CoA changes in
freshly isolated human platelets. Both frataxin knockdown cells and platelets from FA
patients were found to have decreased acetyl-CoA: succinyl-CoA ratio compared to
controls. This represents the first time platelets have been used as a platform to measure
changes in acyl-CoA profiles in FA. In addition to the findings in this study, using LCMS methodology to measure metabolic changes in platelets may lead to novel biomarkers
of FA as well as other metabolic and neurodegenerative diseases.
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6.2 Introduction
Friedreich’s ataxia (FA) is an autosomal recessive disease of mitochondrial
dysfunction and the most common inherited form of ataxia.174 FA results from a
trinucleotide (GAA) expansion repeat in the first intron of the frataxin gene (FXN),
reducing levels of frataxin protein. While the exact role of frataxin is still unknown, it is
believed to be involved in ISC formation.175-177 This expansion leads to decreased
efficiency of ISC-containing enzymes such as those found in complex I-III of the electron
transport chain, as well as aconitase, a critical enzyme which converts citrate to isocitrate
in the Krebs cycle.178 Diminished frataxin expression as well as decreased complex I
activity occurs in a number of different tissues of FA patients.179, 180 This leads to loss of
dorsal root ganglia neurons accompanied by loss of peripheral nerve sensory fibers.180
FA has several characteristic clinical features. The loss of dorsal root ganglia,
typically in early childhood or adolescence, leads to degeneration of the dorsal columns,
which results in the characteristic ataxia and eventually loss of ambulation. In addition, a
large number of patients develop insulin intolerance and diabetes mellitus.174, 180, 181 In
the later stages of FA, hypertrophic cardiomyopathy is often the cause of death.182
Current therapeutic strategies include the use of coenzyme Q, PPARγ agonists, iron
chelators, N-acetylcysteine, idebenone, vitamin E, and ubiquinone, though all have
limited efficacy.174, 175, 179, 183-187 The lack of good biomarkers limits early detection and
hampers attempts to rationally design new therapeutic interventions.188 As a result, most
cases are detected clinically, when significant neuronal damage has already occurred.
The pervasive multi-organ involvement of this mitochondrial disease, with selective
tissue involvement of a severe clinical nature, is similar to that seen with rotenone
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treatment in rats,156 and like with rotenone, may involve an underlying metabolic cause.
In fact, a proteomic study in rats with frataxin knockdown, showed large changes in
proteins involved in energy homeostasis and alternative energy pathways.189 Consistent
with proteomic changes seen in the animal model, we hypothesized that there could likely
be significant metabolic changes that might be observed in both an in vitro frataxin
knockdown model as well as in FA patients.
LC-MS methodology represents a highly sensitive and specific platform for
biomarker development.91 As demonstrated throughout this thesis, CoA thioesters reflect
both short term and long term metabolic changes in physiological, toxicological and
pathological settings. Unlike organic acids and acyl-carnitines, which can be found in
higher abundance in plasma and urine, CoA species are largely intracellular and as such,
require extracts from tissues or cells to be used as biomarkers of disease. Since the
primary pathology of FA is in cardiomyocytes and dorsal column neurons,180 which are
located in clinically inaccessible tissues, a surrogate tissue is required for CoA
measurements. Surrogate tissues are tissues from an individual that may reflect the
disease state, though may not exhibit a pathological phenotype. These can include buccal
cells, dermal fibroblasts or blood cells such as red blood cells (RBCs), lymphocytes or
platelets. As far as blood cells, RBCs have no mitochondria, and as such do not contain a
significant amount of CoA thioesters and therefore would not reflect a mitochondrial
pathology. Lymphocytes and platelets represent extractable tissues containing
mitochondria that can be used not only to measure baseline metabolic differences for
screening, but can also be isolated and subjected to both ex vivo challenges to toxins or
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isotopic tracer MS analysis to further reveal underlying metabolic and mitochondrial
disease.
Since frataxin levels are lower in blood cells including platelets,190 we
hypothesized that platelets might exhibit baseline differences in their CoA profile. In
particular, since aconitase activity is decreased in FA,191, 192 we hypothesized that
platelets of FA patients would exhibit altered levels in the intracellular levels of succinylCoA compared to healthy individuals. In this chapter, we studied the effects of an in
vitro frataxin knockdown using siRNA on the intracellular levels of various short chain
acyl-CoA species. In addition, we looked at baseline differences among FA patients and
age-matched controls in freshly isolated platelets.

6.3 Materials and Methods
6.3.1 Materials
Reagents for LC-MS measurements of short chain acyl-CoA species are described
in section 3.3. 8.5 mL acid citrate dextrose Vacutainer tubes (Whole Blood Tube w/
Anticoagulant, ACD Sol A) were purchased from BD Biosciences (REF 364606).
Frataxin (144470) and negative control siRNAs were purchased from Ambion.

6.3.2 Cell culture and knockdown experiments
Frataxin knockdown experiments were performed by Eric Deutsch in the lab of
David Lynch. HEK293 cells were maintained in minimum essential medium (Invitrogen)
supplemented with 7.5%/2.5% FBS/HS (Foundation/GIBCO), 1% pen strep (GIBCO),
and 200 nM L-glutamine (GIBCO) at 37C, 5% CO2. Within 24 h, when cells had
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reached 40-50% confluency, cells were transfected for 48 h with frataxin or scramble
siRNA. Knockdown success was verified by western blot using an antibody directed
toward mature frataxin protein (Mitosciences), and was expressed as a percentage of
frataxin in parallel control samples. CoA analysis was performed as previously described.

6.3.3 Short chain acyl- CoA measurements in platelets
FA patients were recruited by the Friedreich Ataxia Research Alliance (FARA)
and were seen at the Children’s Hospital of Philadelphia as part of an ongoing,
multicenter natural history study. In addition, age-matched volunteers were used as
controls. All subjects provided written informed consent before participating in study
procedures. Blood was collected in 8.5 mL glass acid citrate dextrose Vacutainer tubes
and transferred into 15 mL centrifuge tubes. Cells were spun at 129g for 15 min with no
brakes. The upper platelet rich plasma (PRP) layer was transferred to a fresh tube and
spun at 341g for 15 min to pellet platelets. Platelets were resuspended and sonicated in 1
mL of 10% TCA and frozen down and stored at -80°C. Prior to SPE purification and
LC-MS analysis, samples were thawed and spiked with 0.2 mL acid extracted SILEC
standards. SPE extraction of short chain acyl-CoA species as well as LC-MS parameters
used in analysis are described in Chapter 3.6. The analysis was performed in two
different sets. The first set included 4 FA patients, and 4 healthy controls, while the
second study included 8 FA patients and 4 healthy controls. The data from the two
studies were combined for meta-analysis. A schematic of the protocol used in platelets is
diagrammed in figure 6.1.
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6.4 Results
6.4.1 siRNA knockdown of frataxinφ
HEK293 cells were transfected with either frataxin siRNA or scramble siRNA
(negative control). Western blot analysis of frataxin protein was used to assess
knockdown efficiency. Frataxin was knocked down greater than 80% in FA patients as
compared to controls after 48 hours (Figure 6.2).

6.4.2 siRNA knckdown results in changes to short chain acyl-CoA profile
Transfected HEK293 cells (48 h) were processed for short chain acyl-CoA as
previously described except in 6-well plates instead of 10 cm dishes. As such, only the
more abundant CoA species (acetyl-CoA, succinyl-CoA, CoASH) were readily detected
and analyzed. There was a significant change in the absolute quantity of acetyl-CoA and
succinyl-CoA in the frataxin knockdown cells as compared to the scramble control cells.
In particular, when the ratio of acetyl-CoA to succinyl-CoA was assessed, there was a
significant decrease in the ratio of acetyl-CoA: succinyl-CoA, contrasting what we
observed with rotenone treatment in cell lines.

6.4.3 CoA measurements in freshly isolated human platelets
The SILEC method developed throughout this report was adapted for CoA
measurements in platelets. In most ex vivo platelet studies, platelets are generally
purified from whole blood followed by washing and resuspension in a standardized
buffer such as Tyrode’s solution. However, we were interested in baseline levels of these

φ

This work was performed by Eric Deutsch in the lab of David Lynch.
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Figure 6.2 Frataxin siRNA knockdown. HEK293 cells were transfected with either
scrambled siRNA (negative control), or frataxin siRNA for 48 hours. (A) Western blot
analysis of frataxin protein siRNA treated cells. (B) Intracellular levels of acetylCoA:succinyl-CoA in control and fxn knockdown cells. Each group was performed in
triplicate. Error bars are SEMs * p < 0.05.
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CoA species since we suspected that persistent metabolic stress among FA patients may
be reflected in surrogate tissues such as platelets, which are known to have decreased
complex I activity. Due to the dynamic nature of metabolites, platelet processing times
were reduced as much as possible. To accomplish this, we removed the wash and
resuspension steps and simply purified platelets with a two-step centrifugation process,
followed by sonication in 10% TCA in the presence of SILEC internal standards. This
reduced the amount of time and exogenous stimuli that would affect platelets and deviate
from baseline differences. In lieu of normalizing CoA levels to blood volume or platelet
counts, which can introduce additional error or increase processing time, we decided to
determine absolute counts of the various CoA species and express them as molar ratios to
one another, i.e. acetyl-CoA: succinyl-CoA ratio. The advantage of this approach is that
it controls for differences in both volume of blood draw and platelet concentration which
we found can vary as much as three-fold from one subject to another. In addition to
platelets, Ficoll-extracted lymphocytes and brushed buccal cells from the cheek were
analyzed. Both lymphocytes and buccal cells were found to have inadequate CoA
material, (data not shown), likely due to lower mitochondrial content. Platelets were
divided into equal fractions and processed. They were found to have adequate precision
for all measured species with RSD < 15% when normalized with SILEC internal
standards.

6.4.3 Friedreich’s ataxia patients have decreased acetyl-CoA:succinyl-CoA
The method developed for platelets was applied to FA patients and age-matched
controls. FA patients were found to have increased levels of succinyl-CoA in their
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platelets. In fact, when these were normalized to acetyl-CoA levels, there was a
significant decrease in the ratio of acetyl-CoA:succinyl-CoA (Figure 6.3). Other short
chain acyl-CoA species were measured, though none appeared to have a significant
correlation with FA. This decrease in acetyl-CoA:succinyl-CoA ratio is consistent with
changes seen in frataxin knockdown model in vitro, though opposite to the changes seen
with rotenone treatment, in which succinyl-CoA levels decreased relative to DMSO
controls.

6.5 Discussion
In this study, we have demonstrated the application of platelets as a platform to
measure baseline acyl-CoA concentrations using stable isotope dilution mass
spectrometry. This method was applied to FA, a mitochondrial disease involving
metabolic dysfunction. FA patients exhibited significant baseline differences in major
short chain acyl-CoA thioester species, consistent with changes exhibited in frataxin
knockdown in vitro, namely a decrease in the molar ratio of intracellular acetyl-CoA to
succinyl-CoA, driven largely by increases in succinyl-CoA. Although we also
anticipated that platelets from FA patients would exhibit similar changes to what we had
seen with rotenone treatment in cells, the effect we found was actually the opposite of
what we expected. That is, rather than a decrease in succinyl-CoA, FA subjects exhibited
an increase in succinyl-CoA. Though the underlying cause is not clear, it may signify
compensatory changes made by the cells to overcome a metabolic deficiency.189 This
could arise from increased anaplerotic flux from odd chained fatty acids or glutamate.193
On the other hand, this could be a result of Krebs cycle stalling, resulting in an inhibition
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Figure 6.3 Acetyl-CoA: succinyl-CoA ratio in platelets in FA subjects vs. controls. Short
chain acyl-CoA species form 12 FA subjects and 8 healthy controls were analyzed using
the previously described methods.
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and decreased consumption of succinyl-CoA. If this is the case, appropriate ex vivo
challenges such as galactose treatment rather than glucose may lead to faster or slower
metabolic decompensation to reveal an underlying mitochondrial dysfunctional state.194
Interestingly, although it has been shown that platelets of FA patients have decreased
complex I expression and activity, FA patients do not exhibit significant disease at
baseline in their blood cells.190 Moreover, FA patients not generally have any clinically
significant deficiencies in hemostasis or platelet function, and yet still displayed
differences in platelet metabolites. This further strengthens the hypothesis that the global
metabolic changes in FA are occurring in all tissues, however, certain tissues are more or
less susceptible to the pathophysiological complications of these changes.189
There are several improvements are being considered for this approach. Although
significant differences were observed, subjects also showed considerable variability,
which may have arisen in various ways. One source is diurnal metabolic variability.
Also, levels of various metabolites may widely vary in the blood or urine from the same
patient after meals or after a long fast. One potential method of controlling for this
variability is by drawing the blood and taking urine samples in the morning, simulating a
fasted state, or after a standardized glucose challenge, representing a fed state. Otherwise,
to bring out the phenotype, an appropriate challenge may be necessary, such as placing
platelets in Tyrode’s containing only galactose to make them more reliant on OXPHOSderived ATP.194 Then, mitochondrial or OXPHOS dysfunction may be revealed through
changes in metabolic or viability parameters. In summary, we have shown that in vitro
models of mitochondrial dysfunction result in metabolic changes that can be detected in
surrogate tissues of diseased individuals with the same genetic defect. Further studies
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with ex vivo metabolic challenges may further uncover FA phenotypes and lead to
functional diagnostic tests for FA, which currently has no clinically practical validated
biomarkers.195 Furthermore, a well-characterized mitochondrial genetic disease such as
FA represents an extremely valuable model to characterize the metabolic pathogenesis of
mitochondrial dysfunction and the identification of characteristic biomarkers induced by
this dysfunction.
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Chapter 7: Development of an ex vivo metabolic challenge model in platelets to
characterize mitochondrial and metabolic physiology
7.1 Abstract
In this chapter, an ex vivo metabolic challenge model is developed in freshly
isolated human platelets. To achieve this, platelets were isolated and purified from
whole blood and treated with propionate, rotenone or stable isotope metabolic tracers
([U-13C6]-glucose, [6-13C1]-glucose [1-13C1]-propionate, [1,2-13C2]-acetate, and
[13C315N1]-pantothenate). Subsequently, short chain acyl-CoA species were extracted
and analyzed using SILEC standards to determine changes in absolute CoA
concentrations, or isotopomer distribution analysis was performed to determine relative
flux with metabolic tracers. Platelets treated with 10 mM propionate were found to have
a greater than 100-fold increase in propionyl-CoA after 1 h. Also, 1 µM rotenone
treatment in platelets resulted in a greater than 90% decrease in succinyl-CoA and a 10
fold increase in BHB-CoA concentration. Both propionate and rotenone-mediated
changes were consistent with previous in vitro experiments performed on human cell
lines. In addition, isotopic tracers were readily incorporated and detected in endogenous
platelet CoA thioesters after only one hour of incubation. Remarkably, [1,2-13C2]-acetate
labeled more than 70% of acetyl-CoA, HMG-CoA, and BHB-CoA, as well as 30% of
succinyl-CoA, when spiked directly into whole blood or after platelet isolation.
Therefore, platelets were found to be a viable, metabolically active, ex vivo challenge
model that can be adapted for diagnostic toxicological and metabolic functional tests.
This methodology can be further used to uncover phenotypic differences in mitochondrial
and metabolic diseases.
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7.2 Introduction
There has been tremendous difficulty in developing and validating biomarkers of
disease.196 Biomarker candidates often show promise pre-clinically, but often have poor
performance in predicting disease during later stages of clinical development or when
used for larger studies.197 The two most critical criteria in the success of biomarkers are
sensitivity and specificity, with both ideally being greater than 90%.198 Although many
candidate biomarkers have adequate sensitivity, lack of specificity for many of these
biomarkers leads to false positives, which decreases the clinical utility of these tests. For
metabolomic biomarkers, in particular, the dynamic nature of metabolite levels adds
another level of complexity.199 Unlike proteins, which are often stable for hours or days,
endogenous metabolites can turn over in seconds and can also exhibit diurnal
variability.200 In addition, if not properly handled, concentrations of these metabolites can
be drastically affected by improper or inconsistent sample collection and processing, due
to their dynamic nature. Like urinary and serum metabolites, tissue and cell metabolites
such as CoA thioesters can also be affected by these same factors. Moreover, since the
measurements are done from cells, which are active biological systems themselves,
quenching of cellular and enzymatic activity is also critical during the assay. It is
possible that the variability observed in the FA study (chapter 6) may be partly attributed
to some of the biological these effects (diurnal variability, sample handling, diet, etc.).
There are various strategies used to overcome or normalize for this variability.
One method is using a functional test rather than a traditional biomarker.201 Traditional
biomarkers may include a metabolite or protein that is persistently elevated or reduced in
a particular disease state. In a functional test, however, a specific challenge is given,
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either in vivo or ex vivo, to uncover phenotypic differences between healthy and diseased
individuals that may not be readily discernible when using baseline measurements. One
example of a functional test is a fasting blood glucose test in which glucose
measurements are given after overnight fasting, thereby reducing the impact of recent
food intake. The level of circulating glucose represents a subject’s ability to
appropriately regulate insulin and store glucose, and is elevated in diabetes mellitus
(Types I and II) as well as certain cancers. A oral glucose tolerance test can also be used,
in which the subject is given an oral glucose load followed by sequential blood glucose
measurements.202 Both fasting and oral glucose tests highlight the use of an exogenous
challenge to reveal an underlying pathological phenotype, in this case, the inability to
properly regulate glucose levels. Most importantly, these types of tests establish an
experimental baseline so that all subjects have approximately similar initial conditions.
Although HbA1C, a sugar-modified circulating hemoglobin, is a more preferable and
predictive biomarker of diabetes progression largely due to its longer half-life in the
blood, this type of biomarker is more common in proteomics than in metabolomics due to
the longer half-life and stability of proteins in biological systems. 203
Although both glucose tests are in vivo challenges, this approach can be
performed ex vivo as well. In an ex vivo test, a small samples of cells or tissues are
extracted and isolated from the subject. These are then challenged with a specified
stimulus in hopes of uncovering a particular phenotype.204 The disadvantage of this
method is that a subset of cells is being studies in isolation rather than looking at the
system wide physiological effects as is done in a glucose load test. The advantage,
however, is that a much larger variety of tests can be used, including pharmacological or
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toxicological tests that would be unsafe or unethical to perform in vivo, such as rotenone
treatment. In addition, since a smaller amount of cells are being tested, a much smaller
amount of reagent or testing compound is required for the test as this does not have to
become systemically distributed. This is particularly useful for isotopic tracer analysis, in
which the reagents may be prohibitively expensive and impractical to perform in vivo
dosing tests.
We hypothesized that this functional test biomarker approach could be used in
platelets ex vivo to help diagnose mitochondrial or metabolic diseases such as FA. To
achieve this, three methodological approaches are pursued in this chapter. First, freshly
isolated platelets were washed and treated with propionate to verify whether platelets
could be used as a metabolically viable ex vivo surrogate tissue. Second, isolated
platelets were subjected to dose-dependent rotenone treatment to determine if the
metabolic activity seen in the cells lines (Chapter 5) can be recapitulated in an ex vivo
toxicological model. Finally, isolated platelets were treated with various isotopic tracer
molecules to determine whether metabolic flux could be assessed in this model. A
schematic of the experimental protocol is provided in figure 7.1.
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Figure 7.1 Scheme for isotopic tracer analysis and ex vivo platelet “challenges.”

7.3 Methods
7.3.1 Materials
[6-13C1]-glucose was purchased from Cambridge Isotopes (Andover, MA). All
other materials used in this chapter were obtained as previously reported.

7.3.2 Isolation and preparation of human platelets
Platelet extraction was performed similarly to what was presented in Chapter 6,
with some modifications. Briefly, whole blood was drawn into 8.5 mL ACD Vacutainer
tubes (BD), transferred to 15 mL falcon tubes and spun for 15 min at 129g with no
brakes. The upper PRP layer was transferred to a fresh tube and spun again at 341g for
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20 min with no brakes. This pellet was resuspended in 5 mL HEN wash buffer (150 mM
NaCl, 1 mM Na2EDTA, 10 mM HEPES, pH 6.5) and was spun again at 329g with no
brakes for 15 min. Finally the platelet pellet was resuspended in 1 mL Tyrode’s solution
(139 mM NaCl, 3 mM KCl, 17 mM NaHCO3, 12 mM glucose, 3 mM CaCl2, 1 mM
MgCl2) and transferred to 1.5 mL microcentrifuge tubes. A 10 µL aliquot was
transferred for platelet counts which were performed on a BD platelet counter in the
laboratory of Dr. Skip Brass.

7.3.2 Ex vivo platelet “challenges”
Ex vivo challenges were performed on resuspended platelets in Tyrode’s solution.
Figure 7.1 illustrates the overall experimental design. Briefly, three different challenge
paradigms were performed. (1) Propionate challenge: a stock of 1mM propionate was
prepared in water. 10 µL of this solution was added to platelets in Tyrode’s solution for a
final concentration of 10 mM. 10 µL of water was used as control. Incubations were
performed in triplicate. (2) Rotenone challenge: a 10 mM stock of rotenone was freshly
prepared in DMSO. Serial 10-fold dilutions were made in DMSO from 1 mM down to
100 pM along with a 5 µM and 500 nM dilution. Platelets from an 8.5 mL blood draw
were resuspended in 10 mL of Tyrode’s solution and divided into equal 1 mL fractions.
10 µL of each rotenone dilution and DMSO control were then added to each to generate a
dosing curve from 1 pM to 100 µM in concentration. (3) Metabolic tracer analysis.
Stocks of five different stable isotope labeled metabolic tracers were prepared in water in
the following concentrations: [U-13C6]-glucose (100 mg/mL), [U-13C1]-glucose (100
mg/mL), [1-13C1]-propionate (1M), [1,2-13C2]-acetate (1M), and [13C315N1]-pantothenate
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(0.3 mg/mL). 10 µL of each stock was added to different tubes of resuspended platelets
(1:100 dilution) for a final concentration of 1 mg/mL, 1 mg/mL, 10 mM, 10 mM, and 3
mg/L, respectively. For all three experiments, platelets were gently mixed by inversion
and incubated in the presence of challenge at 37°C for 1 h. After incubation, platelets
were spun down and short chain acyl-CoA species were extracted as described in chapter
6. In the case of isotopic tracer analysis, no SILEC standards were used. Finally, we also
evaluated the labeling of [1,2-13C2]-acetate spiked directly into whole blood (pre-spin) or
into Tyrode’s solution after washing and purifying (post-spin). In both cases, we used 1
mM [1,2-13C2]-acetate. In the case of pre-spin labeling, we harvested the platelets in the
same fashion as was performed in Chapter 6, (without the HEN wash or Tyrode’s
solution incubation). This decreased the total time from blood draw to acid extraction
down to approximately 45 min.

7.4 Results
7.4.1 Propionate challenge
Freshly isolated human platelets were treated with 10 mM propionate in Tyrode’s
solution. After 30 minutes, propionyl-CoA levels increased 10-fold and concentrations
of acetyl-CoA and succinyl-CoA were significantly decreased (Figure 7.2). These results
are consistent with in vitro experiments in Hepa 1c1c7 cells (Figure 2.6), in which there
was a similar increase in propionyl-CoA and decrease in acetyl-CoA and succinyl-CoA
after propionate treatment observed. Therefore, this propionate challenge demonstrated
that platelets could be used ex vivo as a metabolic functional test platform. This can be
further extended to include other fatty acids or nutrients as well.
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Figure 7.2 Effect of propionate treatment on selected CoA-thioesters in isolated human
platelets. Platelets from one healthy subject were isolated, washed and resuspended in
either Tyrode’s solution or Tyrode’s solution containing 10 mM propionate for 30
minutes. Following incubation, platelets were pelleted and processed for short chain
acyl-CoA concentrations using SILEC methodology. A small aliquot was taken after
resuspension to measure platelet concentration. Each group was performed in triplicate.
* p < 0.005.
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7.4.2 Rotenone challenge
Platelets isolated from an 8.5 mL blood draw were divided into 10 equal fractions
and treated with increasing doses of rotenone for 1 h, followed by short chain acyl-CoA
thioester analysis (Figure 7.3). Rotenone decreased intracellular succinyl-CoA levels and
increased BHB-CoA levels in a dose-dependent manner, both with a IC50 of < 100 nM,
consistent with the effect observed in various cell lines. Moreover, the ratio of BHBCoA: succinyl-CoA was plotted as a function of rotenone dose, demonstrating a likely
relationship between these processes (Figure 7.3). These data show that platelets can be
used as ex vivo toxicological model, and can potentially be used to evaluate the effect of
mitochondrial toxins in different disease states.

7.4.3 Isotopic tracer challenge
Platelets were isolated from three different subjects and treated with metabolic
tracers for 1 h, followed by CoA extraction. Natural mass isotopomer distribution was
calculated in unlabeled platelets and subtracted using a matrix analysis from the labeled
cells to determine the relative isotopic labeling of each isotopomer (Figure 7.4). Both
[13C]-glucose reagents showed minor labeling. However, with [1,2-13C2]-acetate (10
mM), more than 60% of acetyl-CoA was labeled indicating that acetate may be a more
sensitive metabolic tracer to evaluate metabolic flux in the Krebs cycle during shorter
incubations. More strikingly, the BHB-CoA gets labeled in M2 and M4, (but not M1 and
M3) and HMG-CoA get labeled as the M2, M4 and M6 (not M1, M3 or M5), consistent
with incorporation of 2 carbon units from acetate. Also, succinyl-CoA is labeled in M2,
M3 and M4 positions indicative of multiple turns of the Krebs cycle. [1-13C1]-propionate
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Figure 7.3 Dose-dependent effect of rotenone on succinyl-CoA and BHB-CoA in isolated
human platelets. Platelets from one healthy subject were isolated, washed and
resuspended in either Tyrode’s solution containing an increasing concentration of
rotenone for 30 min. Following incubation, platelets were pelleted and processed for
short chain acyl-CoA concentrations. A small aliquot was taken after resuspension to
measure platelet concentration. Figures (A) and (B) demonstrate intracellular platelet
BHB-CoA and succinyl-CoA levels, respectively. Figure (C) demonstrates the ratio of
BHB-CoA to succinyl-CoA.
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was incorporated into [1-13C1]-propionyl-CoA (M1) and was also incorporated into
succinyl-CoA (M1), with approximately 30% of the total succinyl-CoA being labeled
through this anaplerotic pathway. This reagent could potentially be used as an
anaplerotic biomarker by measuring the incorporation of this carbon into succinyl-CoA.
Finally, [13C315N1]-pantothenate (1mg/L) was readily incorporated into each of the
measured CoA species, though at different percentages, suggesting different rates of
turnover for each CoA thioester. The lack of significant M4 isotopomer from the control
cells makes this an ideal labeling reagent for isotopic tracer analysis, as nearly all of the
M4 isotopomer comes from the labeling agent. Furthermore, the greater increase in
[13C315N1]-pantothenate labeling (such as seen in HMG-CoA) is indicative of newly
formed CoA, and suggests a higher turnover or increased synthesis of this product.
Therefore, using [13C315N1]-pantothenate tracing, in addition to evaluating tracers in the
acyl moiety, we can also evaluate the labeling of the CoA backbone. The lack of labeling
in CoASH with the remaining tracers confirmed that the isotopic labeling occurred in the
acyl group.
Due to the rapid labeling observed with 10 mM [1,2-13C2]-acetate labeling, we
evaluated the labeling at 1 mM, to decrease the tendency of the high acetate
concentration sequestering the CoA pool. We also evaluated labeling at two different
points in the protocol. Either (1) directly into whole blood (pre-spin) or (2) after washing
and purification (post-spin), followed by CoA analysis. We found that both pre-spin and
post-spin techniques successfully labeled the cells and was relatively consistent among
the healthy subjects (Figure 7.5). Many of the findings observed at 10 mM were also
seen at 1 mM. Further decreasing the concentration of [1,2-13C2]-acetate or performing a
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Figure 7.5 [1,2-13C2]-acetate labeling of selected CoA thioesters in freshly isolated
human platelets. For pre-spin labeling, whole blood from three different control subjects
was spiked with 1 mM [13C2]-acetate, and processed as illustrated in figure 7.1. For postspin labeling, platelets were isolated, washed and resuspended in 1 mL glucose-free
Tyrode’s solution containing [13C2]-acetate (1 mM) for 1 h. Following incubation,
isotopic distribution of selected CoA species was determined. Unlabeled blood was used
in both instances to determine baseline isotopomer distribution.
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tracer dosing study should be evaluated. Since the pre-spin application of isotopic tracers
was successful in labeling these CoA species, a commercially available blood collection
tube containing the labeling reagent of interest dissolved in the buffer represents a
powerful and clinically applicable diagnostic tool.

7.5 Discussion
In this chapter, we have shown that freshly isolated human platelets can be used
as an ex vivo platform for a variety of challenges or functional tests. This type of test
could be used to characterize metabolic physiology or uncover metabolic and
mitochondrial pathophysiology. First, we demonstrated that in 1 h, an exogenous fatty
acid such as propionate can be incorporated into propionyl-CoA in platelets. This could
potentially be used as a diagnostic tool for a disease like propionyl-CoA carboxylase
deficiency.205, 206 Insufficient downstream products or a buildup of propionyl-CoA may
reveal an enzymatic deficiency.
Second, the rotenone challenge model revealed another potentially powerful
application of this method. We demonstrated that rotenone treatment in isolated platelets
recapitulates the phenotype seen with cell lines. This not only further strengthens our
original findings for rotenone-mediated changes in intracellular CoA species (particularly
succinyl-CoA and BHB-CoA), but also demonstrates that platelets are a viable surrogate
tissue to study mitochondrial or metabolic dysfunction. In diseases such as FA, where an
underlying metabolic disease manifests clinically in certain tissues, this type of approach
may be used diagnostically to uncover disease. For instance, FA patients may exhibit
increased sensitivity to rotenone, where a lower dose may exacerbate CoA changes due to
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a lower toxic threshold. Conversely, FA patients may exhibit decreased sensitivity to
rotenone treatment due to metabolic compensation at baseline and increased reliance on
glycolysis. These changes must ultimately be determined empirically. This would not
only improve diagnostic capabilities, but also help us understand pathological
mechanisms that occur in FA. The destruction of a specific group of neuronal cells while
sparing nearby cells, is also a distinctive feature of other neurodegenerative diseases such
as PD, AD, and ALS in which nigrastriatal, cerebral cortical, and spinal motor neurons
are degraded, respectively. Thus, this assay may be useful for other neurodegenerative
diseases as well.
Finally, and perhaps the most valuable application of this methodology is the ex
vivo isotopic tracer analysis. We have demonstrated that in as little as one hour, five
different isotopic tracers were incorporated and could be readily detected in the
metabolites extracted from freshly isolated platelets. In fact, there are hundreds or even
thousands of different stable isotope metabolic tracers that could likewise be used. In
addition to the changes in absolute concentrations of these metabolites, this methodology
allows characterization of the flux through these pathways as well.207 This would
improve diagnostic capabilities for many metabolic diseases. Nonetheless, the proper
tracer, time of application, and sample handling techniques need to be optimized for each
disease. For longer incubations, lymphocytes or fibroblasts could be used since platelets
cannot be cultured overnight.204, 208 In fact, there is evidence that platelets from PD, AD
and ALS patients as well as fibroblasts from AD patients exhibit decreased glutamate
uptake.209-212 Using the methodology developed here, we would not only be able to more
quantitatively analyze glutamate uptake, but by using a labeled glutamate tracer, we
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would be able to determine the fate of the labeled glutamate. Since glutamate can serve
as an anaplerotic substrate, decreased glutamate uptake may manifest in decreased
incorporation of labeled carbons into aKG and downstream metabolites. This is just one
of many potential applications of this assay.
There are certain limitations to this approach over classic biomarker approaches.
In particular, the requirement of fresh viable cells makes logistical clinical application
challenging and also limits any study that proposes using historical or previously
collected samples. In addition, rigorous adherence to standardized protocols would be
required not only for sample collection, but also for ex vivo challenge, extraction and
analysis. Additionally, improper or inconsistent handling could result in significant
metabolic disturbances which could lead to erroneous conclusions. On the other hand, the
ability to collect, wash and resuspend platelets ex vivo prior to testing affords increased
standardization and reduces variability that may arise from previously described external
factors. In total, however, platelets represent not only a novel surrogate tissue to study
metabolism, but these approaches provide a methodological advance in biomarker
development. By using functional metabolic tests, much richer and more dynamic data
sets can be generated than from classical biomarker studies.
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Chapter 8: Conclusions and Future Directions
8.1 Conclusions
In this thesis, we have developed a method to generate SILEC-labeled CoA
standards and utilized them to rigorously measure short chain acyl-CoA thioester in cell
culture, various animal tissues and clinical samples. These not only improved the
specificity of CoA measurement, but also improved accuracy and precision of the
measurements. By utilizing the lack of a de novo biosynthetic pathway, we were able to
generate nearly isotopically pure CoA species biosynthetically in both mammalian and
insect cell lines. The extracted species were then applied to biological samples to
measure changes in CoA molecules. We also improved upon previously developed
isotopic tracer analysis to monitor intracellular flux of labeled carbons through different
pathways by performing isotopomer distribution analysis on the different CoA species.
Together, these methods allowed us to more confidently monitor changes in the absolute
concentration of several important CoA species in cell culture, animal tissue and platelet
samples as well as the turnover and flux through these species in vitro.
Applying these standards to biological samples led to three important findings.
First, using a novel LC-SRM/MS method to monitor intramitochondrial oxidative stress
by monitoring ratio of CoASSG: CoASH, it was found that these levels increased
dramatically at high menadione doses. Similar doses of rotenone, also known to generate
ROS in mitochondria, did not appear to increase these levels, suggesting that CoASSG
may be involved in the detoxification of xenobiotics and electrophiles within the
mitochondria. Second, it was found, that rotenone dramatically changed in the short
chain acyl-CoA thioester profile in a number of different cell lines, including
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neuroblastoma (SH-SY5Y), hepatoma (HepG2) and bronchioalveolar carcinoma (H358)
cells. In particular, rotenone induced a dose-dependent decrease in succinyl-CoA and
increase in BHB-CoA. Isotopic tracer analysis revealed that rotenone inhibited [U-13C6]glucose-derived acetyl-CoA and succinyl-CoA biosynthesis in SH-SY5Y neuroblastoma
cells.
Finally, this SILEC method was adapted for use in freshly isolated human
platelets. Extracted platelets were used to characterize differences in short chain acylCoA concentrations between healthy controls and patients with FA, a mitochondrial
disease for which metabolic dysfunction is known to play a role. A significant decrease
in the acetyl-CoA: succinyl-CoA concentration was observed in FA patients and was
consistent with an in vitro frataxin knockdown model. In addition to being used as a
surrogate source of CoA and mitochondrial metabolites, we also demonstrated that
platelets could be used as a platform for ex vivo metabolic and toxicological challenges.
In addition, we also demonstrated that platelets could be used to trace isotopically labeled
metabolic nutrients through various biochemical pathways.

8.2 Future Directions
8.2.1 Expansion of in vitro, in vivo and ex vivo models
Cancer cell lines were used for the majority of our work with rotenone-induced
metabolic derangement. While cancer cell lines are both easier to work with and are more
uniform between experiments, they are known to differ metabolically from primary lines.
In particular, the Crabtree or Warburg effect, a phenomenon in which cancer cells
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become more glycolytic and may derive as much as 95 % of their ATP from
glycolysis.194, 213 Using rotenone to inhibit mitochondrial respiration in highly glycolytic
cells may not induce as dramatic a phenotype as cells more reliant on mitochondria for
ATP. One method of avoiding this is by replacing glucose with galactose. In the case of
galactose, cells do not generate a net gain of ATP through glycolysis and therefore
become more reliant on mitochondria for cellular ATP. These OXPHOS-dependent cells
are subsequently more sensitive to mitochondrial inhibitors.194 Another way to overcome
this problem is by using primary cell lines, which may more closely resemble the
metabolic state of these tissues in rodents and humans. The drawback to using primary
cells is the difficulty in isolating a particular cell type. In the case of primary neuronal
cells, glial cells often contaminate and complicate the analysis. Nevertheless, a
comparison to primary cells will be important in confirming the changes that are
observed in the cell lines. Preliminary data indeed demonstrates that the rotenonemediated metabolic changes observed with the cell lines (Chapter 5) were recapitulated in
primary cortical rat neurons.
In addition, application to neuronal tissue is actively being pursued. The rotenone
rat model of PD has been widely used and provides a well validated system to study
mitochondrial dysfunction in neurodegenerative disease.152 We hypothesize that chronic
low dose treatment of rotenone in rats will lead to compensatory or pathological
metabolic derangement that will manifest in a variety of tissues including the brain,
though most dramatically in particular regions such as the substantia nigra.

8.2.2 Measuring other organic acids and Krebs cycle intermediates
122

This thesis was primarily focused on changes in short chain acyl-CoA species.
These were important in understanding changes in several metabolites within or proximal
to the Krebs cycle. While understanding changes in acyl-CoA species undoubtedly
improves our ability to explore pathological changes in numerous metabolic pathways, it
only gives us a partial picture. Further studies exploring changes in organic acids such as
those in the Krebs cycle can give us a better understanding of these changes. In fact, we
are currently developing an LC-MS method to measure changes in numerous organic
acids using a derivatization procedure with MTBSTFA, a derivatizing agent commonly
used for GC-MS.163 Using this reagent, we have been able to measure changes and
isotopic labeling in citrate, aKG, succinate, fumarate, malate, oxaloacetate and lactate.
Measurements in pyruvate, isocitrate, acetoacetate, BHB, glutamate, and many other fatty
acid and cellular nutrients are currently being developed. In addition to expanding the
number of metabolites measured, a larger panel of isotopic tracers will be developed to
further explore the effects of rotenone, FA and other mitochondrial diseases in vitro as
well as in platelets.

8.2.3 Measuring the human “CoA-balome”
Throughout this thesis, we have primarily focused on measuring short chain acylCoA species for a number of reasons. Most importantly, these molecules are involved at
the intersection of many central metabolic pathways such as glycolysis, the Krebs cycle
and FAO. Nonetheless, they represent only a small fraction of the many CoA-derivatives
including medium, long and very long chain acyl-CoA thioesters, not to mention
numerous xenobiotic CoA adducts (appendix, Table A.1). In addition, novel CoA
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derivatives such as CoA-RNA adducts and CoA-hydroxynonenal adducts have recently
been discovered, though the function and mechanism of formation of these molecules
remains unclear. 43, 56 Together, all of these species illustrate the complexity as well as
the rich abundance of measurable CoA species. Much like the genome has given way to
the transcriptome, and the proteome can be further dissected into the phospho-proteome,
the human metabolome is also much too complex to be analyzed using a single method.
In fact, the multitude of CoA molecules represent a “CoA-balome,” the subset of all CoA
derivatives, that might require a systems biology approach to study. It is possible, and
even likely, that each mitochondrial or metabolic disease would have a unique CoA
fingerprint either at baseline or under some experimentally induced stress. This may only
be seen in disease-specific tissues, in which case the assays we developed may allow
further understanding of the pathogenic mechanisms of these diseases. On the other
hand, these may exhibit changes in surrogate tissues as well, as growing evidence
suggests underlying metabolic causes for many diseases. The ability afforded by newer
software platforms combined with the ability to do perform CoA discovery using neutral
loss scanning of CoA (m/z 507) would allow a tremendously powerful approach to
diagnosing a variety of diseases. By increasing the breadth of this assay to include a
larger subset of CoA species, and combining it with isotopic tracer analyses, new disease
biomarkers may be discovered for a multitude of diseases.
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Appendix
SILEC
+

+

CoASH

768

772

Formyl-CoA

796

800

Acetyl-CoA

810

814

Acrylyl-CoA

822

826

Propionyl-CoA

824

828

Methacrylyl-CoA

836

840

Crotonoyl-CoA

836

840

Coenzyme A thioester

MH
MH
(amu) (amu)

Butyryl-CoA

838

842

Isobutyryl-CoA

838

842

Beta-Alanyl-CoA

839

843

3-Hydroxypropionyl-CoA

840

844

Lactyl-CoA

840

844

Tiglyl-CoA

850

854

3-Methylcrotonyl-CoA

850

854

Acetoacetyl-CoA

852

856

Isovaleryl-CoA

852

856

Pentanoyl-CoA

852

856

2-Methylbutyryl-CoA

852

856

L-3-Aminobutyryl-CoA

853

857

Malonyl-CoA

854

858

3-Hydroxybutyryl-CoA

854

858

(S)-3-Hydroxyisobutyryl-CoA

854

858

trans-2-Hexenoyl-CoA

864

868

trans-3-Hexenoyl-CoA

864

868

2-Methylacetoacetyl-CoA

866

870

Hexanoyl-CoA

866

870

Succinyl-CoA

868

872

S-Methylmalonyl-CoA

868

872

R-Methylmalonyl-CoA

868

872

Methylmalonyl-CoA

868

872

3-Hydroxyisovaleryl-CoA

868

872

2-Methyl-3-hydroxybutyryl-CoA

868

872

Benzoyl-CoA

872

876

Cyclohex-1,5-diene-1-carboxyl-CoA

874

878

Itaconyl-CoA

880

884

Glutaconyl-CoA

880

884

3-Oxohexanoyl-CoA

880

884

2-Methylhexanoyl-CoA

880

884

Heptanoyl-CoA

880

884

Table A.1 CoA-thioesters and derivatives, including unlabeled and SILEC labeled parent
ion masses (m/z MH+, amu). Previously published (Basu SS, Blair IA. Nat Protocols,
2011).
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SILEC
Coenzyme A thioester

MH+
MH+
(amu) (amu)

Glutaryl-CoA

882

(S)-Hydroxyhexanoyl-CoA

882

886
886

Malyl-CoA

884

888

Salicyl CoA

886

890

Phenylacetyl-CoA

886

890

4-hydroxybenzoyl-CoA

888

892

3-trans,5-cis-Octadienoyl-CoA

888

892

6-Oxocyclohex-1-ene-1-carboxyl-CoA

890

894

2-trans,4-trans-Octadienoyl-CoA

890

894

6-Hydroxycyclohex-1-ene-1-carboxyl-CoA

892

896

(2E)-Octenoyl-CoA

892

896

S-2-Octenoyl CoA

892

896

3-Methylglutaconyl-CoA

894

898

Valproyl-CoA

894

898

Octanoyl-CoA

894

898

Adipoyl-CoA

896

900

L-Citramalyl-CoA

898

902

4-Hydroxyphenylacetyl-CoA

902

906

2,6-Dimethylheptanoyl-CoA

904

908

3-Oxooctanoyl-CoA

908

912

Nonanoyl-CoA

908

912

(S)-Hydroxyoctanoyl-CoA

910

914

(3S)-3-Hydroxyadipyl-CoA

912

916

3-Hydroxy-3-methylglutaryl-CoA

912

916

2,4-Decadienoyl-CoA

918

922

cis-2-Methyl-5-isopropylhexa-2,5-dienoyl-CoA

918

922

trans-2-Methyl-5-isopropylhexa-2,5-dienoyl-CoA

918

922

(2E)-Decenoyl-CoA

920

924

4-cis-Decenoyl-CoA

920

924

trans-3-Decenoyl-CoA

920

924

trans-D-Decenoyl-CoA

920

924

Decanoyl-CoA (n-C10:0CoA)

922

926

3-Oxopimelyl-CoA

924

928

3-Hydroxypimelyl-CoA

926

930

Pseudoecgonyl-CoA

935

939

3-Hydroxy-2,6-dimethyl-5-methylene-heptanoyl-CoA

936

940

3-Oxodecanoyl-CoA

936

940

Undecanoyl-CoA

936

940

4,8-Dimethylnonanoyl-CoA

936

940

Table A.1 CoA-thioesters and derivatives (cont.)
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SILEC
Coenzyme A thioester

MH+
MH+
(amu) (amu)

(S)-Hydroxydecanoyl-CoA

938

942

(2E)-Dodecenoyl-CoA

944

948

cis,cis-3,6-Dodecadienoyl-CoA

946

950

trans,cis-Lauro-2,6-dienoyl-CoA

946

950

Trans-2,3-dehydrododecanoyl-CoA

948

952

3Z-dodecenoyl-CoA

948

952

Lauroyl-CoA

950

954

E-Phenylitaconyl-CoA

956

960

(R)-Benzylsuccinyl-CoA

958

962

3(S)-3-hydroxydodecen-(5Z)-oyl-CoA

960

964

(3S)-3-Hydroxydodec-cis-6-enoyl-CoA

960

964

3-Oxododecanoyl-CoA

964

968

(S)-3-Hydroxydodecanoyl-CoA

966

970

(3E,5Z,8Z)-Tetradecatrienoyl-CoA

968

972

(2S,6R,10R)-Trimethyl-2E-hendecenoyl-CoA

972

976

2-Carboxymethyl-3-hydroxyphenylpropionyl-CoA

974

978

(2S,6R,10R)-Trimethyl-hendecanoyl-CoA

974

978

5-cis-8-cis-Tetradecadienoyl-CoA

974

978

(2E)-Tetradecenoyl-CoA

976

980

Tetradecanoyl-CoA

978

982

trans-2-Enoyl-OPC4-CoA

986

990

(3S)-3-Hydroxy-cis-8-tetradecenoyl-CoA

988

992

OPC4-CoA

988

992

3-Oxotetradecanoyl-CoA

992

996

(S)-3-Hydroxytetradecanoyl-CoA

994

998

(4R,8R,12R)-Trimethyl-2E-tridecenoyl-CoA

1000

1004

(2E)-Hexadecenoyl-CoA

1000

1004

Palmitoleyl CoA

1004

1008

Palmitelaidoyl-CoA

1004

1008

Palmitoyl-CoA

1006

1010

(3S)-3-Hydroxy-cis,cis-palmito-7,10-dienoyl-CoA

1014

1018

trans-2-Enoyl-OPC6-CoA

1014

1018

(S)-3-hydroxypalmitoleoyl-CoA

1016

1020

OPC6-CoA

1016

1020

3-Oxohexadecanoyl-CoA

1020

1024

Heptadecanoyl CoA

1020

1024

(S)-3-Hydroxyhexadecanoyl-CoA

1022

1026

Stearidonoyl-CoA

1026

1030

Gamma-linolenoyl-CoA

1028

1032

Table A.1 CoA-thioesters and derivatives (cont.)
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SILEC
+

+

Alpha-Linolenoyl-CoA

1028

1032

Linoleoyl-CoA

1030

1034

trans-Octadec-2-enoyl-CoA

1032

1036

cis-Vaccenoyl CoA

1032

1036

Oleoyl-CoA

1032

1036

Stearoyl-CoA

1034

1038

(3S)-3-Hydroxylinoleoyl-CoA

1042

1046

trans-2-Enoyl-OPC8-CoA

1042

1046

OPC8-CoA

1044

1048

3-hydroxyoctadecanoyl-CoA

1046

1050

3-Oxooctadecanoyl-CoA

1046

1050

Retinoyl CoA

1050

1054

Timnodonyl CoA

1052

1056

3-Hydroxyhexdecanedioyl-CoA

1052

1056

5Z,8Z,11Z,14Z-eicosatetraenonyl-CoA

1054

1058

Arachidonyl-CoA

1054

1058

Pristanoyl-CoA

1062

1066

Eicosanoyl-CoA

1062

1066

Phytanoyl-CoA

1062

1066

Glutathione-CoA (CoASSG)

1073

1077

2,4,7,10,13,16,19-Docosaheptaenoyl-CoA

1076

1080

Clupanodonyl CoA

1076

1080

2-Hydroxyphytanoyl-CoA

1078

1082

Docosa-4,7,10,13,16-pentaenoyl CoA

1080

1084

Docosanoyl-CoA

1086

1090

8Z,11Z,14Z-eicosatrienoyl-CoA

1096

1100

Trans-2-all-cis-6,9,12,15,18,21-tetracosaheptaenoyl-CoA

1100

1104

Tetracosahexaenoyl CoA

1106

1110

Tetracosatetraenoyl CoA

1110

1114

(3S)-Hydroxy-tetracosa-6,9,12,15,18,21-all-cis-hexaenoyl-CoA

1118

1122

Tetracosanoyl-CoA

1118

1122

Chenodeoxyglycocholoyl-CoA

1142

1146

Chenodeoxycholoyl-CoA

1142

1146

Hexacosanoyl-CoA

1142

1146

Choloyl-CoA

1158

1162

3a,7a-Dihydroxy-5b-cholest-24-enoyl-CoA

1182

1186

3a,7a-Dihydroxy-5b-24-oxocholestanoyl-CoA

1198

1202

3a,7a,12a-Trihydroxy-5b-cholest-24-enoyl-CoA

1198

1202

Coenzyme A thioester

MH
MH
(amu) (amu)

Table A.1 CoA-thioesters and derivatives (cont.)
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Day

Acetyl-CoA

Succinyl-CoA

CoASH

HMG-CoA

Propionyl-CoA

1

5.3

18.3

1.0

0.3

0.2

2

13.0

29.9

2.4

0.5

0.4

3

32.3

80.9

19.1

2.3

1.0

4

110.0

152.9

47.3

8.0

3.7

5

91.9

213.1

91.9

4.0

6.0

6

78.3

108.0

75.8

0.9

2.0

7

68.0

84.5

118.0

0.8

1.9

Table A.2 Amounts of intracellular CoA thioesters formed (pmol/plate) on days after
splitting mouse Hepa cells. Previosuly published in Basu et al. Anal Chem, 2011,
Supporting Information.

Stable Isotope Internal Standard

CoA

CoASH

Succinyl-CoA HMG-CoA Acetyl-CoA Propionyl-CoA

CoASH

0.9966

0.9922

0.9877

0.9948

0.9922

Succinyl-CoA

0.9652

0.9996

0.9937

0.9982

0.9991

HMG-CoA

0.9688

0.9996

0.9939

0.9993

0.9983

Acetyl-CoA

0.8443

0.9978

0.8098

0.9990

0.9958

Propionyl-CoA

0.9585

0.9992

0.9975

0.9983

0.9999

Table A.3 Correlation coefficients for linearity of standard curves for various CoA
species using SILEC standards (bold) compared with structural analog internal standards
(normal). Previosuly published in Basu et al. Anal Chem, 2011, Supporting Information.
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HepG2

SH-SY5Y

Acetyl-CoA

H358

BHB-CoA

Propionyl-CoA

DMSO

8.68

+ 0.70

Succinyl-CoA
3.37

+ 0.10

2.42

CoASH
+ 0.17

0.065 + 0.002

0.047 + 0.003

0.59

+ 0.01

10pM

7.05

+ 0.33

2.88

+ 0.30

3.12

+ 1.28

0.065 + 0.002

0.036 + 0.006

0.64

+ 0.02

100pM

8.99

+ 0.33

2.98

+ 0.07

2.97

+ 0.87

0.070 + 0.001

0.042 + 0.006

0.62

+ 0.07

1nM

9.53

+ 0.51

2.48

+ 0.10

3.52

+ 0.21

0.079 + 0.008

0.049 + 0.002

0.83

+ 0.12

10nM

8.21

+ 0.18

2.23

+ 0.09

2.13

+ 0.32

0.086 + 0.002

0.041 + 0.002

0.73

+ 0.06

100nM

9.54

+ 0.74

0.99

+ 0.02

1.93

+ 0.30

0.177 + 0.008

0.019 + 0.003

1.05

+ 0.16

1uM

10.25 +

0.21

0.66

+ 0.04

2.19

+ 0.57

0.241 + 0.027

0.010 + 0.003

1.05

+ 0.21

DMSO

11.46 +

0.44

9.52

+ 0.81

10.76 +

1.50

0.170 + 0.008

0.704 + 0.029

2.02

+ 0.21

+ 0.72

10pM

8.78

100pM

11.49 +

1nM

9.35

10nM

10.13 +

0.93

100nM

10.51 +

0.15

4.39

+ 0.23

5.36

1uM

12.05 +

0.46

2.08

+ 0.06

DMSO

14.76 +

0.82

7.48

10pM

12.32 + 0.29

100pM

12.20 +

0.43

1nM

10.94 +

10nM

11.44 +

HMG-CoA

6.78

+ 0.35

6.73

+ 0.43

0.150 + 0.003

0.601 + 0.037

1.60

+ 0.04

0.62

7.71

+

0.45

8.77

+

1.07

0.164 + 0.002

0.740 + 0.049

1.76

+ 0.10

+ 0.85

7.21

+ 0.69

6.09

+ 0.67

0.163 + 0.019

0.586 + 0.035

1.84

+ 0.20

7.25

+ 0.13

6.78

+ 0.35

0.170 + 0.011

0.783 + 0.035

2.29

+ 0.08

+ 0.41

0.325 + 0.012

0.735 + 0.018

2.00

+ 0.08

5.42

+ 1.17

0.582 + 0.003

0.719 + 0.059

2.10

+ 0.16

+ 0.60

5.82

+ 1.12

0.158 + 0.006

0.157 + 0.005

2.08

+ 0.19

7.36

+ 0.20

4.86

+ 0.41

0.160 + 0.015

0.157 + 0.011

1.85

+ 0.04

7.83

+ 0.40

4.44

+ 0.08

0.152 + 0.006

0.146 + 0.001

1.83

+ 0.23

0.91

7.02

+ 0.12

5.13

+ 0.69

0.212 + 0.010

0.179 + 0.018

1.62

+ 0.07

0.16

6.28

+ 0.20

5.19

+ 0.42

0.358 + 0.002

0.222 + 0.011

1.91

+ 0.19

+ 0.65

2.39

+ 0.13

3.45

+ 0.19

0.713 + 0.006

0.174 + 0.005

1.17

+ 0.11

1.30

+ 0.14

3.87

+ 0.57

1.103 + 0.101

0.150 + 0.015

1.36

+ 0.07

100nM

9.05

1uM

10.44 +

0.34

Table A.4. Absolute levels of CoASH and several short chain acyl-CoA thioesters in SHSY5Y cells treated with rotenone measured using SILEC methodology. Concentrations
are presented as pmol/106 cells +/- SEM (triplicate). When compared to DMSO controls,
p < 0.05 (italics) and p < 0.005 (bold). Published in Basu, Blair. Chem Res Toxicol, 2011.
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2.0e4
1.0e4
0.0

868.1361.1
1

2

3

4

5

6

7

8

9

2.0e4
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3000
2000
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0
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[13C 3, 15N]- Succinyl-CoA
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3

4

5
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8
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8

9.36 10.77
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[13C
1

2

3

3

916.1409.1
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4

5

6

7

8

9
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1

2

3

4

5

6

7

8

9
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9.19
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1
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6

7

8
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1
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3

4

5

6

7

8
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2

3

4

5

6

7

8
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8.81
9
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Figure A.1 LC-SRM/MS chromatogram of acid extracted SILEC-labeled short chain
acyl-CoA internal standards demonstrating isotopic purity. Previosuly published in Basu
et al. Anal Chem, 2011, Supporting Information.
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